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Background. Although antipsychotic medications are primarily intended to treat schizophrenia and 
psychotic symptoms in adults, they are commonly administered to nursing home residents as 
pharmacotherapy for “off-label” indications such as disruptive behaviour. However, clinical trials have 
demonstrated limited efficacy and serious side-effects of antipsychotics among the elderly. As previous 
studies have reported inappropriate use in several countries, their use in nursing home residents ought to 
be monitored to detect and reduce inappropriate administration.  
Objectives. The aim of this study was a) to determine and compare prevalence rates of antipsychotic 
use in Ontario and Swiss nursing homes, b) to identify determinants of antipsychotics use in these two 
countries, by means of a cross-sectional design, and c) to investigate the impact of antipsychotic use on 
behaviours over time in Ontario and Swiss residents, by means of a longitudinal design. 
Methods. This study involved secondary data analysis of 1932 residents from 24 nursing homes in the 
province of Ontario in Canada and 1536 residents from 4 nursing homes in a German-speaking canton 
in Switzerland. Residents were assessed with the Minimum Data Set (MDS) tool. Resident 
characteristics and prevalence rates were compared internationally with the chi-square test. 
Demographic and clinical determinants of antipsychotic use, as well as behavioural change associated 
with antipsychotics, were analyzed using logistic regression.  
Results. Although Ontario nursing home residents had an overall heavier-care profile than Swiss 
residents, antipsychotics were administered to 25% of the Ontario residents compared to 29.5% of the 
Swiss residents. The adjusted rate among residents without appropriate conditions was also lower in 
Ontario (14%) than in Switzerland (24.5%). Apart from schizophrenia, bipolar disorder and cognitive 
impairment, antipsychotic use was determined by a different range of characteristics in these two 
countries. Antipsychotic use was not predictive of behavioural improvement.  
Conclusion. The high adjusted rates of antipsychotic use in Ontario and Swiss nursing home residents, 
as well as the presence of ”inappropriate indications” and “facility” as determinants of their use, raise 
concerns about the appropriateness of their administration in both countries. Their lack of effectiveness 
to improve behaviours also questions their use as long-term treatment for behaviour disturbances. 
Changes in practice patterns and implementation of policies are warranted to reduce inappropriate 
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1. INTRODUCTION 
Antipsychotic medications have been used since the 1950s to treat schizophrenia, signs and symptoms 
of psychosis, and commonly used to treat agitation, mood instability and behaviour disturbances in the 
elderly (Tandon, Milner & Jibson, 1999; Glick, Murray, Vasudevan, Marder & Hu, 2001). However, 
clinical trials and reviews have suggested limited efficacy of antipsychotics and serious adverse side-
effects in older populations (e.g. Lanctôt et al., 1998; Neil, Curran & Wattis, 2003; Lee et al, 2004). The 
US Food and Drug Administration (FDA) and Health Canada also released a Public Health Advisory in 
2005 on the increased risk of death associated with the use of antipsychotic drugs in elderly patients 
with behaviour disturbance and dementia1. Despite this side-effect profile, a number of studies have 
reported the excessive and inappropriate use of antipsychotics in nursing home residents (Ray, 
Federspiel & Schaffner, 1980; Beers et al., 1992; Schmidt, Claesson, Westerholm & Svarstad, 1998; 
Oborne, Hooper, Chi Li, Swift & Jackson, 2002). Thus, concerns have arisen for many years about 
antipsychotic use2 in nursing homes. In the US, evidence of misuse in nursing homes led to legislation 
limiting their use in 1990 (Stoudemire & Smith, 1996).  
The prevalence of antipsychotic use in nursing homes has previously been recorded, mostly in 
the US, for monitoring purposes. Few studies further considered the demographic and clinical 
characteristics of antipsychotic recipients to uncover practice patterns, using a systematic and 
standardized assessment tool. Some studies have identified residents’ characteristics associated with 
antipsychotic use in an inconsistent manner, such as younger age, dementia, aggressive behaviour, 
restlessness, greater mobility, and being physically restrained (e.g. Briesacher et al., 2005; Voyer et al., 
2005). Structural variables, such as size of the institution and staffing level, have not been consistently 
related to antipsychotic prescriptions (Ray et al., 1980; Buck, 1988). Thus, researchers have suggested 
that antipsychotic use was determined by patient characteristics rather than institutional variables 
 
1 http://www.fda.gov/cder/drug/advisory/antipsychotics.htm and 
http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/atyp-antipsycho_hpc-cps_e.html 
2 antipsychotic use will refer to antipsychotic administration throughout this study 
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(Buck, 1988). Fewer studies have examined outcomes associated with antipsychotic use in actual 
clinical practice on large samples. Such studies have suggested mixed improvement in behaviours 
(Burton, Rovner, German, Brant & Clark, 1995), cognitive decline (McShane et al., 1997), increased 
falls and fractures (Ray, Blazer, Schaffner & Federspiel, 1987), and urinary incontinence (Lindesay, 
Matthews & Jagger, 2003).  
Therefore, the primary focus of this research was to determine and compare the prevalence rates 
of antipsychotic use in nursing homes in two different countries, Canada and Switzerland. Second, the 
demographic and clinical characteristics of recipients were investigated in both countries separately, to 
uncover practice patterns. Third, the impact of antipsychotic use on specific behaviours was explored 
using longitudinal data. 
After reviewing the literature on the use of antipsychotics in the elderly, the research questions of 
this study are outlined. Then, the methodology section provides a description of the data collection tool, 
the samples, the variables and the statistical analyses pertaining to the research questions. After 
presenting the results, their discussion follows, with suggestions for future research and implications for 
practice and policy. 
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2. LITERATURE REVIEW 
This literature review provides an overview of: a) the two types of antipsychotics,  b) the effectiveness 
of antipsychotics in the elderly with a focus on efficacy, adverse side-effects and functional outcomes; 
the published guidelines for their use in the elderly; and the existing regulations in nursing homes; c) 
the prevalence and incidence of antipsychotic use in nursing homes; the appropriateness of 
antipsychotic administration; and the demographic, clinical and structural characteristics associated 
with their use; and d) the value of international comparisons; a brief description of nursing homes in 
Canada and Switzerland; and previously reported use of antipsychotics in these two countries. 
2.1. Neuroleptics and Atypical Antipsychotics 
Antipsychotic medication is a psychotropic drug along with anxiolytics, hypnotics and antidepressants. 
Antipsychotics are divided into typical or conventional agents, and atypical agents, the newer 
generation1. The conventional antipsychotics, introduced in the 1950’s, are referred to as neuroleptics 
(“seize the neurons”), and are generally associated with extrapyramidal side effects (EPS) (Tandon et 
al., 1999). A new generation of antipsychotics was developed during the 1990’s to produce fewer side-
effects, and is called atypical as it separates the antipsychotic therapeutic effect from the extrapyramidal 
side effect (Tandon et al., 1999; Neil et al., 2003). Both types of antipsychotics can be prescribed on a 
regular basis or on an as-needed basis (pro re nata). 
Neuroleptics are primarily intended to treat schizophrenia in adults (Neil et al., 2003), but can 
also be prescribed for medical and psychiatric conditions associated with psychotic symptoms such as 
depression with psychosis, manic episode of bipolar disorder, Huntington’s disease, Tourette’s 
syndrome and aggressive behaviour associated with dementia (Tandon et al., 1999; Glick et al., 2001).  
Atypical antipsychotics have recently replaced conventional antipsychotics as the new standard 
of care for schizophrenia and bipolar disorder (Ghaemi, 2000). In the elderly, atypical antipsychotics 
 
1 In this study, the term ‘neuroleptic’ refers to conventional antipsychotic; ‘atypical antipsychotic’ refers to the 
newer generation; and ‘antipsychotics’ refer to both types. 
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are commonly used as a pharmacotherapy for other conditions as “off-label” indications, such as 
agitation associated with dementia (Glick et al., 2001). However, in Canada, only one atypical agent is 
approved for the short-term management of aggressive behaviour disturbances in elderly patients with 
dementia (Pwee, Shukla, Herrmenn & Skidmore, 2003).  
2.2. Antipsychotics and the Elderly 
Conventional and atypical agents are mostly used in the elderly as a pharmacotherapy for psychosis and 
agitation associated with dementia, usually described under the umbrella term of behavioural and 
psychological symptoms of dementia (BPSD) (Finkel, Costa e Silva, Cohen, Miller & Sartorius, 1996). 
These BPSDs include delusions and hallucinations, agitation, wandering, restlessness, hostility, 
uncooperativeness, sleep disturbance, depression or anxiety, and disturbed mood (Finkel, 2001). For 
instance, antipsychotics were prescribed for restlessness as the diagnostic indication in 40% of the 
prescriptions, for psychotic symptoms in 27% of the cases, and for agitation in 7% of the cases in a 
Norwegian study (Ruths, Straand & Nygaard, 2001). Current knowledge on the effectiveness of 
antipsychotics in the elderly to treat these symptoms, as well as published guidelines on appropriate and 
inappropriate conditions for antipsychotic treatment are reviewed in the following sections. 
2.2.1. Effectiveness 
The effectiveness of antipsychotics relates to their ability to produce an overall beneficial effect in 
actual practice. More precisely, clinical effectiveness covers four domains: the efficacy of 
antipsychotics, which is their ability to control or relieve the targeted symptoms (e.g. psychotic 
symptoms); their tolerability and safety, measured by the rate of adverse side-effects; the functional 
outcomes, such as their impact on the level of physical functioning and cognition, and the quality of 
life; and their acceptability, where compliance is the major factor (Lalonde, 2003). The efficacy, safety 
and functional outcomes of antipsychotics in the elderly are reviewed in this section. 
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Efficacy
The efficacy of antipsychotics in the elderly has mostly been investigated in randomized controlled 
trials (RCT), focusing on their efficacy to manage agitation and improve BPSD. To measure the 
efficacy, RCTs have used a range of behavioural scales as primary outcome of interest, such as the 
Behavioural Pathology in Alzheimer’s Disease Rating Scale (BEHAVE-AD) (De Deyn et al., 1999; 
Katz et al., 1999), the Brief Psychiatric Rating Scale (BPRS) (Barnes, Veith, Okimoto, Raskind & 
Gumbrecht, 1982; Yoon, Kim, Lee, Shin & Choi, 2003), or the Cohen-Mansfield Agitation Inventory 
(CMAI) (DeDeyn at al, 1999). Overall, RCTs and reviews suggests that conventional antipsychotics are 
only moderately effective in the elderly to manage acute behaviour problems, and that no neuroleptic is 
consistently more effective (Schneider, Pollock & Lyness, 1990; Lanctôt et al., 1998; Sunderland & 
Silver, 1988; Devenand, Sackeim & Mayeux, 1988; Helms, 1985; Burton et al., 1995). The evidence for 
the efficacy of atypical antipsychotics in reducing BPSD is more pronounced, but side-effects remain 
common (Lee et al, 2004; Katz et al., 1999; DeDeyn et al., 1999; Pwee et al., 2003; Glick et al., 2001; 
Yoon et al., 2003). Findings from key studies on the efficacy of neuroleptics and atypical antipsychotics 
are summarized in Appendix A, as well as the design, the sample and the outcome measures.  
The RCTs reporting evidence for the efficacy of antipsychotics in reducing disruptive behaviours 
should be interpreted with caution. First, efficacy is often mitigated by improvements in the placebo 
group as well, possibly due to the increased attention patients received (Katz et al., 1999; DeDeyn et al., 
1999; Pwee et al., 2003). Second, consensus on outcome measures and the threshold of significant 
improvement is lacking, limiting comparisons across studies (Pwee et al., 2003). Third, the quality of 
studies is of concern as very few reviewed studies meet quality criteria (Helms, 1985; Pwee et al., 
2003). Finally, publication bias may be present, if articles showing improved behaviour with 
antipsychotics were favoured for publication over studies with negative findings. 
Only two studies were found in the literature investigating the efficacy of antipsychotics in actual 
practice. Burton and colleagues (1995) examined the change in nine disruptive behaviours in residents 
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treated with neuroleptics, using the Psychogeriatric Dependency Rating Scale (PGDRS). A larger 
proportion of users compared to non-users improved in three behaviours: restlessness, wandering, and 
exhibiting objectionable behaviour. Either the development or the resolution of disruptive behaviour 
was suggested to occur among residents regardless of neuroleptic use, but occurred more frequently 
among neuroleptic users. However, potential confounding variables were not controlled for. The second 
study, using the MDS assessment tool, found that residents administered antipsychotics were at 
increased risk for developing wandering behaviour (Kiely, Morris & Algase, 2000). The authors 
suggested that antipsychotics may cause confusion leading to wandering behaviour, or that wandering 
was the actual target of treatment and not present at baseline as it was sufficiently controlled for, but 
developed later because of tolerance.  
Adverse Side Effects
Antipsychotics, whether conventional or atypical, are associated with many side-effects in the elderly, 
and can increase the risk of death. For instance, antipsychotics contributed the most frequently to 
overall medication problems in a Norwegian study examining drug-related problems in nursing home 
residents (Ruths, Straand & Nygaard, 2003).  
Most common side-effects are extrapyramidal symptoms (EPS), such as pseudo-parkinsonism, 
tardive dyskinesia (repetitive movement) and akathisia (inability to remain still), anti-cholinergic 
symptoms, and sedative effects, such as orthostatic hypotension (Maixner, Mellow & Tandon, 1999; 
Masand, 2000; Neil, Curran & Wattis, 2003). The atypical antipsychotics have a slightly better side-
effect profile than conventional, with fewer EPS, lower risk of dyskinesia and less movement disorders 
(Glick et al., 2001). Antipsychotic recipients were also found to be at increased risk for falls, hip 
fractures, insomnia and abnormal gait, resulting from the sedative side-effect (Hien et al., 2005; Ray, 
Griffin, Schaffner, Baugh & Melton, 1987; Maixner et al., 1999, Neil et al, 2003; Katz et al., 1999). 
Voyer and colleagues (2005) suggested that antipsychotic users had more problems sleeping than non-
users. Urinary incontinence has also been reported as side-effect in the elderly (Lindesay et al., 2003).  
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The risk of side-effect is of special concern in the institutionalized elderly, because of their 
increased vulnerability resulting from physiological changes induced by the aging process, and from 
polypharmacy due to comorbidities. The elderly have a higher sensitivity to extrapyramidal symptoms 
and tardive dyskinesia than younger users, due to how the aging process affects medication 
metabolization (Maixner et al., 1999; Masand, 2000). In addition, nursing homes residents are more 
likely to suffer from multiple medical problems requiring drug treatments than elderly living at home 
(Furniss, Lloyd Craig & Burns, 1998). Studies have shown that nursing homes residents in the US are 
prescribed on average between 7.2 and 8.1 medications (Beers et al., 1988, Beers et al., 1992). Such 
prescribing practices increase the risk of adverse effects due to drug interactions (Maixner et al., 1999.) 
Finally, concerns have recently arisen about the increased risk of death for the elderly receiving 
atypical antipsychotics. Hence, public health advisories were issued in several countries warning about 
the use of atypical agents in the elderly. Concerned about the potential risk of death associated with 
conventional agents, Wang and colleagues (2005) conducted a retrospective cohort study involving 
22,890 patients who received both types of antipsychotics between 1994 and 2003. Their results 
suggested that both atypical and conventional agents increase the risk of death among elderly persons.  
Functional Outcomes
Cognition and physical functioning in the institutionalized elderly are important outcomes as they 
impact their quality of life, which is an important consideration in determining the effectiveness of a 
treatment (Ballard & Margallo-Lana, 2004). However, the positive and negative effects of 
antipsychotics on functional and cognitive domains have not been extensively researched (Beers et al, 
1988; Sunderland & Silver, 1988; Lawlor, 2001).  
Neuroleptic use has been associated with an increased rate of cognitive decline in the elderly 
(McShane et al., 1997; Devenand et al., 1989). However, these two studies were based on small 
samples (n=71 and n=9 respectively) and McShane’s sample consisted of non-institutionalized elderly. 
RCTs, generally using the Mini-Mental State Examination (MMSE) as outcome measure, did not find 
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significant adverse effect on cognition (Yoon et al., 2003; Katz et al., 1999). De Deyn and colleagues 
(1999) found that cognitive function deteriorated among neuroleptic users, but not among atypical 
users. Byerly and colleagues (2001) concluded from their review that some elderly patients may 
experience adverse cognitive effects when using antipsychotics.  
Studies investigating the effect of antipsychotics on Activities of Daily Living (ADL) in the 
elderly are sparse and were mostly done in schizophrenic patients (Masand, 2004). Yoon and colleagues 
(2003) investigated the impact on ADL in 48 Korean demented patients and found no significant 
change. However, the sample size was small, limiting the interpretation of the results. 
The limited effectiveness of antipsychotics, their adverse side-effects profile, and the potential 
adverse impact on cognition and ADL warrant precautious use in the institutionalized elderly. Hence, 
guidelines were produced to guide the prescription of antipsychotics in the elderly. 
2.2.2. Guidelines 
Generally applicable guidelines for the prescription of antipsychotics in the elderly are difficult to 
specify, as each individual has unique characteristics. However, such guidelines are necessary to guide 
care and decision-making, as benefits of antipsychotic use are weighted with many adverse side-effects. 
In the US, the first governmental guidelines for antipsychotic use in the elderly in nursing homes 
were developed in 1987 by the Health Care Financing Administration (HCFA) defining the appropriate 
and inappropriate indications, which are regularly updated by the Centres for Medicare and Medicaid 
Services (CMS) (formerly know as HCFA) (Stoudemire & Smith, 1996; Gurvich & Cunningham, 
2000). In parallel, expert consensus guidelines were produced in the Journal of Clinical Psychiatry for 
the use of antipsychotic agents in older patients in general in 2004 (Alexopoulos, Streim, Carpenter & 
Docherty, 2004). Their goal was to offer guidance on the use of antipsychotics in the elderly by 
identifying: 1) the geriatric disorders for which antipsychotics are inappropriate; 2) the indications for 
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the use of antipsychotics in the elderly, as well as recommended drug, dosage and duration of treatment 
according to the condition treated; and 3) the most likely disease-drug and drug-drug interactions.  
In brief, these CMS guidelines (DHHS & CMS, 2002) and expert consensus guidelines 
(Alexopoulos et al., 2004) consider antipsychotics to be appropriate for patients with: schizophrenia, 
delusional disorder, psychotic mood disorder (including mania and depression with psychotic features), 
acute psychotic symptoms (such as delusions and hallucinations), Tourette’s disorder, Huntington’s 
disease, and organic mental syndromes (delirium and dementia) associated with psychotic and/or 
agitated behaviour causing danger to the resident or others and resulting in distress or impairment of 
functional capacity. On the other hand, antipsychotics were considered inappropriate for patients with: 
generalized anxiety disorder, panic disorder, non-psychotic depression, insomnia or sleep disturbances, 
and non-endangering agitated behaviours, such as wandering, restlessness, fidgeting or nervousness, 
unsociability, indifference to surroundings, and uncooperativeness.  
2.2.3. Regulations 
Antipsychotic prescription in the institutionalized elderly is neither regulated nor controlled in both 
Canada and Switzerland. In the United States, neuroleptics have been the target of legislation in 
response to the growing concern of neuroleptics being used as form of chemical restraint rather than 
part of a specific treatment (Harrington, Tompkins, Curtis & Grant, 1992). This legislation, the 
Omnibus Budget Reconciliation Act [OBRA]-87, was implemented in 1990. This legislation requires 
the documentation in the resident’s medical record of the specific conditions for which antipsychotics 
are prescribed. Appropriate indications are specified in interpretative guidelines - presented in the 
precedent paragraph - to protect residents from receiving antipsychotics without proper written 
indication and documentation (Stoudemire & Smith, 1996). Antipsychotic use significantly decreased 
in nursing homes following the implementation of OBRA-87 (Shorr, Fought & Ray, 1994; Liperoti et 
al., 2003; Rovner, Edelman, Cox & Schmuely, 1992). However, recent studies (e.g. Briesacher at al., 
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2005) have shown that their use has increased over time, partly due to the introduction of atypical 
antipsychotics. 
2.3. Empirical Literature on Antipsychotic Use in Nursing Homes 
As previously mentioned, antipsychotics are mostly used in nursing homes as a pharmacotherapy for 
the BPSD, as they can be quite problematic when they put the resident or others at risk for injury and 
interfere with resident’s care. The following sections present the prevalence and incidence use of 
antipsychotics, the appropriateness of antipsychotic administration in nursing homes, as well as the 
characteristics associated with antipsychotic use in nursing homes.  
2.3.1. Prevalence and Incidence 
Literature on the prevalence of antipsychotic use in nursing homes is abundant. Appendix B provides an 
overview of prevalence and incidence rates reported in the literature. Overall, the rates of antipsychotic 
use vary substantially from 8% to 62%. However, high prevalence rate is not necessary an indicator of 
excessive use. It could be justified by the overall characteristics of residents in the nursing homes with 
regards to their health condition and length of stay. For instance, nursing homes specialized in caring 
for demented patients with psychosis will likely have a higher rate of use than nursing homes only 
accepting light-care residents. Another explanation to the wide prevalence range reported in the 
literature is the data collection methodology with regards to the source of information and the time-
interval of data collection. Garrard and colleagues (1992) established that prevalence rates based on 
prescription orders and claims files are more likely to be higher than those based on actual use or 
administration, as prescribed drugs might not be actually administered. Beers and colleagues (1988) 
found that an average of 8.1 medications were prescribed, of which 4.7 were actually administered. The 
length of the observation period can also inflate the rate, as residents are more likely to be administered 
antipsychotics within a 12-month period than within 7 days (e.g. Bronskill et al., 2004).  
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2.3.2. Appropriateness 
Prevalence estimates are not sufficient to determine whether antipsychotics are appropriately and not 
excessively prescribed. The indication for antipsychotic administration should also be assessed based 
on clinical criteria to determine whether their use is appropriate. The CMS guidelines were previously 
used to assess the appropriateness of antipsychotic prescriptions in nursing homes, by reviewing 
prescriptions or medical files (McGrath & Jackson, 1996; Oborne et al., 2002; Briesacher et al., 2005). 
For instance, among nursing home residents prescribed neuroleptics in the UK, only 12% and 17.8% 
were prescribed antipsychotics appropriately (McGrath & Jackson, 1996; Oborne et al., 2002). Reasons 
for inappropriateness were: inappropriate indication (mild agitation, wandering, uncooperativeness, 
insomnia); indication not documented; and dose reduction not attempted. On the other hand, 41.8% of 
users in US nursing homes received antipsychotics in accordance with these guidelines (Briesacher et 
al., 2005),. This higher rate of appropriateness is likely due to the OBRA-87 regulation.  
Zimmerman and colleagues (1995) developed quality indicators (QIs) of antipsychotic use to 
monitor the quality of care in nursing homes and to track changes over time, based on the CMS 
guidelines and using clinical information collected with the MDS assessment tool. The QI is risk-
adjusted for resident-level risk factors to correct for differences in residents characteristics over which 
nursing homes have little or no control. Residents with a diagnosis of schizophrenia or with 
hallucinations are considered appropriate users and are excluded from the risk-adjusted QI. The high-
risk QI is adjusted for residents with potentially appropriate indications: residents being verbally or 
physically abusive, or showing socially inappropriate behaviour, associated with cognitive impairment, 
indicated by presence of problems in decision-making and short-term memory deficits. The low-risk QI 
represents the rate of antipsychotic use among all other residents without appropriate indications.   
Appropriateness of antipsychotic use in nursing home residents (n=139,714) was previously 
examined in the US according to these QIs: among appropriate users, 68.3% received antipsychotics; 
among potentially appropriate users (high risk), 18.2% received antipsychotics; and among potentially 
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inappropriate users (low risk), 3.9% received antipsychotics (Liperoti et al., 2003). The authors 
concluded that these figures indicated good practice and inappropriate use was a limited phenomenon.  
The risk-adjustment strategy for the QIs was later modified using statistical regression-based 
covariate adjustment strategy for resident- and facility-level covariates, and were referred to as 
MegaQIs (Kidder et al., 2002). However, the QIs for antipsychotic use are no longer recommended for 
public reporting in the US as they were not validated in the report submitted to the CMS (Morris et al., 
2003). The number of preventive or responsive validation elements (existing strategies to minimize the 
emergence or recognize the presence of problems) for these QIs was limited and these elements did not 
achieve high correlation with the QIs.  
Nevertheless, the appropriateness of antipsychotic prescribing in the institutionalized elderly is an 
on-going issue, as previous studies have shown that actual practice in nursing homes differed from 
published guidelines. Thus, the appropriateness of their use among nursing home residents ought to be 
regularly assessed in order to monitor the quality of care.  
2.3.3. Characteristics associated with Antipsychotic Use 
Demographic, clinical, behavioural, physical, cognitive, and structural characteristics have been 
associated with antipsychotic use in the literature. Much of this literature examined a range of 
characteristics in bivariate analyses (only one explanatory variable) and/or multivariate analyses (more 
than one explanatory variable) using cross-sectional data. However, direct associations between 
antipsychotic use and the characteristic of concern (i.e. bivariate association) are of limited interest, as 
the relationship maybe confounded by third variables. Summaries of the main studies, with information 
on sample size, data collection method, and central findings are presented in Appendix B. Here is 
reviewed evidence supporting the relationship between antipsychotics and a range of characteristics.  
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Demographic Characteristics
Antipsychotic use was associated with being male in bivariate analyses, but not in multivariate (Ruths 
et al., 2001; Burton et al., 1995; Lindesay et al., 2003; Nygaard et al., 1990). Ruths and colleagues 
(2001) suggested that the overuse by men in bivariate was due to their younger age, which is associated 
with antipsychotic use. Younger age was significantly associated with antipsychotic use in some studies 
(Lindesay et al., 2003; Ruths et al., 2001; Voyer et al., 2005; Castle, 1999), whereas not associated in 
other studies (Nygaard et al., 1990; Briesacher et al., 2005;). For instance, the younger old (65 to 74) 
were found to be three times more likely to receive antipsychotics than the older old (over 85) (Voyer et 
al., 2005). An explanation suggested by Voyer and colleagues (2005) is that antipsychotics are more 
likely to be prescribed to residents in better health, thus in the younger age group.  
Clinical Diagnoses
Clinical diagnoses of schizophrenia, bipolar disorder, and psychotic conditions (such as hallucinations 
and delusions) were associated with antipsychotics use as expected, as these clinical diagnoses are the 
principal target of antipsychotic treatment (Spore, Horgas, Smyer & Marks, 1992; Draper et al., 2001; 
Sorensen, Foldspang, Gulmann & Munk-Jórgensen, 2001; Briesacher et al., 2005).  
The association between antipsychotic use and the diagnoses of dementia and Alzheimer’s 
disease is a more problematic issue, as antipsychotics can be prescribed for these diagnoses if they are 
associated with psychotic symptoms, such as verbal or physical aggression, delusions or hallucinations. 
Thus, when investigating the relationship between antipsychotics and dementia, psychotic symptoms 
should be introduced as a confounding variable. Nevertheless, dementia was found to be a significant 
and independent determinant of antipsychotic use regardless of psychotic symptoms (Spore et al., 1992; 
Castle, 1999; Draper et al., 2001).  
The association between depression and antipsychotics is problematic in a similar manner, as 
depression with psychosis can be treated with antipsychotics. It has however not been extensively 
investigated, and studies do not report whether depression was associated with psychosis. Castle (1999) 
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found that residents on antipsychotics suffered significantly more from depression compared to non-
users. Even though anxiety is not an indication for antipsychotics, Castle (1999) also found that 
residents receiving antipsychotics were more likely to suffer from anxiety disorders. Anxiety was also 
the primary target in 10% of the antipsychotic prescriptions in Norway (Ruths et al., 2001). 
Behavioural Characteristics
The relationship between antipsychotics and the BPSD is problematic to interpret in cross-sectional 
studies, as associated behaviours can either be triggers for antipsychotic use, consequences of 
antipsychotic use or consequences of other factors, such as polypharmacy or physical comorbidities. In 
addition, studies have measured disruptive behaviour in different ways, limiting comparisons and 
overall interpretations. 
For instance, antipsychotic use has been associated in multivariate analyses with displaying at 
least one disruptive behaviour measured with the CMAI scale (Voyer et al., 2005), and with offensive 
behaviour defined as behaviour causing others distress or discomfort (Lindesay et al., 2003). In 
Briesacher and colleagues’ study (2005), almost 40% of users had behavioural problems, and 11% of 
appropriate users had worse behavioural symptoms (measured by the MDS item on general 
deterioration of behaviour within last 90 days). Antipsychotic users were also found to be agitated more 
frequently (Spore et al., 1992) and display restlessness compared to non-users in multivariate analyses 
(Nygaard, Bakket, Breivik & Brudwik, 1990; Nygaard et al., 1994).  
The relationship between antipsychotics and insomnia is unclear. Disturbed sleep and insomnia 
have been reported as independently associated with antipsychotic use in multivariate analyses 
(OR=2.08 and 4.1) (Sorensen et al., 2001; Voyer et al., 2005). A first explanation could be the use of 
antipsychotics for their sedative effect to treat sleep problems, though this is not recommended by 
expets (Sorensen et al., 2001). Antipsychotics were indeed found to be prescribed for insomnia in 6% of 
antipsychotic prescriptions (Ruths et al, 2001). On the other hand, sleep disturbances could be a side-
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effect of antipsychotic use (Voyer et al, 2005). The cross-sectional nature of these studies hinders the 
inference of causal relationships, which can only be verified in longitudinal studies. 
Physical Functioning Characteristics
Studies have investigated the association between antipsychotics and Activities of Daily Living (ADL) 
items, which measure residents’ dependency in various domains such as personal hygiene and 
locomotion. Studies have shown that residents highly dependent in ADL were less likely to be 
administered antipsychotics in multivariate analyses (Lindesay et al., 2003; Castle, 1999), while 
residents with increased mobility were more likely to be administered antipsychotics (Sorensen et al., 
2001; Nygaard et al., 1990). The association with increased mobility was suggested to reflect motor 
restlessness, either as an indicator of resistance to care or as a side-effect of antipsychotic use. Another 
plausible explanation is that less mobile residents are less likely to disturb their surroundings compared 
to mobile residents. However, the association between ADL and antipsychotic use was not significant 
in other studies (Burton et al., 1995; Voyer et al., 2005). 
Cognitive Characteristics
Severe cognitive impairment has been significantly associated with the likelihood of receiving 
antipsychotics in multivariate analyses (Voyer et al., 2005; Lindesay et al., 2005; Castle, 1999). 
However, whether cognitive impairment precedes or results from antipsychotic use is unclear. On one 
hand, disruptive behaviour has been shown to increase with the loss of cognitive functioning in 
individuals with dementia (Voyer et al., 2005). Thus, cognitive impairment and disruptive behaviour 
are strongly associated (Lindesay et al., 2003; Nygaard et al., 1990) and cognitive impairment likely 
precedes antipsychotic use. On the other hand, longitudinal studies have shown that cognition decreased 
in residents receiving antipsychotics (McShane et al., 1997).  
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Physical Restraint
Physical restraint was found to be commonly used with antipsychotic drugs: between 41% and 60% of 
antipsychotic users were also physically restrained in Quebec (Voyer et al., 2005) and in the US before 
the implementation of regulations (Garrard et al, 1992). The use of restraint among antipsychotic users 
could indicate that these two methods are jointly used to deal with disruptive behaviour. 
Structural Variables
The association between antipsychotic use and structural variables has been previously studied, with 
conflicting results. For instance, the relationship between antipsychotic prescriptions and the nursing 
home size was significant in one study (Ray et al., 1980) but not in another study (Ruths et al., 2001). 
Authors have thus concluded that prescriptions of antipsychotics were more likely to be influenced by 
patient characteristics rather than institutional variables (Buck, 1988).  
2.4. International Comparison: Canada and Switzerland 
This study compared the use of antipsychotics in two countries, Canada and Switzerland. International 
comparisons of care settings provide opportunities to uncover differences in care that could not be 
discovered through studies within one jurisdiction. Indeed, care practices from one country can be 
benchmarked with those from other countries, revealing potential different models or standard of care. 
The comparison of practice patterns in nursing homes from two different countries also allow for a 
better understanding of long-term care within each country in contrast with others.  
Canada and Switzerland are both well developed nations with high life-expectancy and a growing 
ageing population. They share the value of caring for the elderly, have similar long term care system 
and face similar challenges. A growing part of the ageing population requires care provided in nursing 
homes, yielding problems of insufficient nursing home beds and problems of quality of care. Indeed, 
the quality of care in nursing homes has become an area of scrutiny in both countries to ensure good 
care to the elderly and concerns about antipsychotic use have arisen in both countries. In Ontario, 
17 
articles have been published about the problematic increase in antipsychotic use in the last 10 years 
(Rapoport et al., 2005) and warnings about the use of atypical antipsychotics in the elderly have been 
posted by the government. In Switzerland, warnings have also been issued in 2004 on the use of 
atypical antipsychotics in the elderly (Ruggli et al., 2004). However, antipsychotics are not regulated in 
either country, unlike the US. Thus, comparing countries facing similar problems and challenges offers 
the possibility to investigate the impact of potential different approaches. 
2.4.1. Nursing Homes in Ontario and Switzerland 
Canada and Switzerland are both composed of a mosaic of health care systems as each province 
(Canada) and canton (Switzerland) has its own health care system with general federal regulations. 
Consequently, nursing homes may differ between provinces and cantons. Information on the long-term 
care system is widely available in Ontario, the most populated province in Canada, but difficult to 
obtain for small cantons in Switzerland. Thus, the long-term care system will be described for Ontario 
specifically and for Switzerland in general. 
In Ontario, nursing homes are designed for people who need the availability of 24-hour nursing 
care, supervision or non-hospital extended personal care. The nursing home facilities are operated by 
for-profit private corporations, municipalities (called homes for the aged) or charities (non-profit 
organizations), but regulated by the government. Indeed, the Ministry of Health and Long-Term Care 
(MOHLTC) sets standards for care and inspects long-term care homes annually. The MOHLTC funds 
the care component, while accommodation is charged to residents based on a co-payment rate set by the 
MOHLTC. Eligibility for and admissions to long-term care facilities is determined by the Community 
Care Access Centres (CCACs) across the province. In 2000, there were about 57,000 long term care 
beds in 498 facilities in Ontario, and beds exceeded 70,000 in 2004 (Smith, 2004).  
In Switzerland, nursing homes provide care for chronically disabled elderly. The majority of 
nursing home facilities are operated by private non-profit enterprises, while some are operated by the 
public sector and for-profit enterprises (Crivelli, Filippini & Lunati, 2002). Similarly to Ontario, 
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residents are expected to pay for the accommodation component, while the government and private 
health insurances share the cost of the care component (DuPasquier & Gilgen, 1999). In 1991, Ribbe 
and colleagues (1997) estimated that there were 72,000 beds in nursing homes (approximately 70 beds 
per 1000 elderly population) with additional 42,000 beds in geriatric wards of general hospitals and 
12,000 beds in psychiatric hospitals.  
2.4.2. Antipsychotic Use in Canadian and Swiss Nursing Homes 
The published literature on antipsychotic use in nursing homes is more abundant in Canada than in 
Switzerland. Canadian studies have reported their use mostly in Ontario and Quebec, and a Swiss study 
was found to report their use in the canton of Vaud. Finally, one study previously compared the use of 
antipsychotics in nursing homes in Quebec and in the French-speaking part of Switzerland. 
Conn and colleagues (1999) examined prescriptions available from pharmacies supplying 
medications to long-term care facilities in Ontario. They found the highest rate of antipsychotic use in 
nursing homes (29.8%) compared to retirement homes. However, information was collected from 
prescriptions rather than actual administration and the sample size (n=436) was small. Bronskill and 
colleagues (2004) examined the incidence use of antipsychotics in Ontario nursing homes on a much 
larger sample size (n=19780). Among residents newly admitted between 1998 and 2000, 17% were 
prescribed antipsychotics within 100 days and 24% within 1 year of admission. In their sample, men 
and residents with dementia were more likely to initiate antipsychotic use. However, their data on 
demographic and diagnostic variables were limited. In Voyer and colleagues’ study (2005), the 
prevalence of antipsychotic consumption by residents in the region of Quebec City was almost 28%. 
Demographic and clinical characteristics of nursing home residents were also investigated and results 
indicated that antipsychotic drug consumption was determined by younger age, few hours of family 
visits, severe cognitive impairment, insomnia, physical restraint and disruptive behaviour.  
Lucas and colleagues (2004) investigated medication prescriptions in all nursing homes from the 
canton of Vaud in Switzerland in 1996. The prevalence of antipsychotic consumption by all the 
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residents in the canton (n=5884) was 43%. In multivariate linear regression, the number of 
antipsychotics administered daily was negatively correlated with age, Parkinson’s disease, severe 
orientation problems, drug addiction and the size of the nursing home. Psychiatric morbidity, agitation, 
disturbing others, impairment in daily decision making, and persistent anxiety increased the likelihood 
of receiving antipsychotics. Clinical variables explained 22% of the variance in antipsychotic 
administration, while the nursing home factor explained 20%.  
Gobert and D’horre (2005) investigated the use of psychotropics in Quebec and in French-
speaking Switzerland in 1998.  They found that 32.9% of long-term care residents in Quebec and 35.9% 
of residents in Switzerland received antipsychotics within the 7 days of assessment. Appropriateness of 
antipsychotic prescription was assessed using daily dosage and departure from average practice as 
criteria. The authors concluded that antipsychotics were not over-used, as the dosage seemed adequate 
and no facility departed from the average practice. However, these criteria for appropriateness are 
clearly limited. First, clinical characteristics of recipients were not considered in the criteria, leading to 
the conclusion of appropriateness when, in fact, antipsychotics were administered for inappropriate 
conditions. Second, antipsychotic use was compared to the average practice within the studied 
population, disregarding whether the average practice was appropriate.  
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3. STUDY RATIONALE 
The study of antipsychotic use in the institutionalized elderly is an essential area of research as residents 
in nursing homes are a particularly vulnerable population. Indeed, their clinical, physical, and cognitive 
status puts them at increased risk for antipsychotic use and their associated adverse side-effects. Thus, 
the prevalence and appropriateness of antipsychotic use and the impact of their use on residents should 
be investigated and monitored for the safety and well-being of nursing home residents, and to ensure 
high quality of care. This research also adds to the limited existing literature on the determinants of 
antipsychotic use in nursing homes in Canada and Switzerland, and on the behavioural outcomes 
associated with their use in nursing home residents. Few studies to date have investigated the outcomes 
of antipsychotic use in the institutionalized elderly, as most studies were randomized, placebo-
controlled trials testing the efficacy of antipsychotics under controlled conditions.  
The purposes of this present study were: 1) to investigate the pattern of antipsychotic use in 
nursing homes; 2) to investigate the impact of antipsychotic use on residents’ behaviours; and 3) to 
compare the findings internationally between Ontario and Switzerland. This international comparison 
was integrated into the first two objectives by benchmarking results from one dataset to the other.  
3.1. Research questions 
3.1.1. Patterns of Antipsychotic Use 
The purpose of the following research questions was to identify patterns of antipsychotic use in the two 
samples of nursing home residents in Ontario and in Switzerland by: describing the two samples; 
determining the prevalence of actual administration of antipsychotics among all residents and among 
residents with appropriate, potentially appropriate and inappropriate indications; and identifying the 
significant determinants of antipsychotic use. 
1) What are the general characteristics of residents in Ontario and Switzerland? 
- International comparison: Are there significant differences in the general characteristics of 
residents between Ontario and Switzerland? 
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2) What is the prevalence of antipsychotic use in Ontario and Switzerland among all residents and 
among residents with appropriate, potentially appropriate and inappropriate indications? 
- International comparison: Is there a significant difference in the prevalence of 
antipsychotic use between Ontario and Switzerland? 
- Longitudinal aspect: What are the incidence and cessation rates of antipsychotics in 
Ontario and Switzerland? 
3) What are the determinants of antipsychotic use in Ontario and Switzerland? 
- International comparison: Do the determinants differ between Ontario and Switzerland? 
3.1.2. Behavioural Outcomes of Antipsychotic Use 
The purpose of the following research questions was to investigate the impact of antipsychotic use on 
behaviours over time in the two samples of nursing home residents in Ontario and in Switzerland 
separately. More specifically, we were interested in determining whether antipsychotic use was 
associated with the incidence, the cessation, the improvement and/or the deterioration of various 
behavioural symptoms between time 1 (T1) and time 2 (T2). 
4) Does antipsychotic use predict the incidence and/or the cessation of the following behaviours: 
wandering, verbally abusive, physically abusive, socially inappropriate, resisting care and 
aggressive behaviour? 
5) Does antipsychotic use predict the improvement and/or the deterioration of the following 
behaviours: wandering, verbally abusive, physically abusive, socially inappropriate, resisting 
care, and aggressive behaviour? 
3.2. Relevance of research  
Literature on the use of antipsychotics in the elderly is abundant, and recommendations for their use in 
the elderly have previously been published for geriatricians. Nevertheless, monitoring their use in the 
elderly is an on-going issue that remains a focus for care-planners, policy makers and the general 
public, especially in these two countries without antipsychotic regulations and in the context of quality 
of care assurance and increasing costs of medications in nursing homes.  
The quality of care in nursing homes has been a central issue for several years. As such, 
information on the pattern of antipsychotic administration is to be continually gathered to monitor their 
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use in order to rapidly detect and report increased use or inappropriate use for quality and safety of care 
purposes. Indeed, accurate and up-to-date information on antipsychotics are necessary for program 
planners to tailor interventions and for policy-makers to improve and ensure the adequacy of 
antipsychotic administration. 
The economical aspect of antipsychotic use is another growing issue, as recent studies have 
reported a large increase in the costs of antipsychotics. In Ontario, results from the cross-sectional time 
series analysis of antipsychotic utilization among all individuals residing in the community over 65 
years old from 1993 to 2002 (Rapoport et al., 2005) showed that the slight increase in the prevalence of 
antipsychotic use was associated with over 200% increase in total antipsychotic prescriptions and 
approximately 750% increase in total cost. In addition, atypical antipsychotics were not available in 
1993, but by 2002, they accounted for 82% of the prescriptions and were responsible for 95% of the 
costs. In Switzerland, a study has shown that the cost of antipsychotics per patient increased 47% 
between 2002 and 2003 in one nursing home, while the cost of antidepressants per patient decreased 
(Ruggli et al., 2004). Upon closer examination, the increase was due to the increase in the cost by 
galenic unit (+19%) and the increase of antipsychotic administration (+34%). This augmentation was 
mostly due to a new and expensive atypical agent. Thus, in light of these high costs associated with 
antipsychotics, the monitoring of their administration to detect and reduce inappropriate administration 
is an important issue for health management policies aiming at rationalizing costs. 
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4. METHODOLOGY 
Analyses were based upon cross-sectional and longitudinal data derived from RAI 2.0 datasets collected 
in nursing homes in Canada and Switzerland. After briefly describing the data collection tool and the 
samples, the proposed methodology is presented separately for the two purposes of this study: (1) the 
pattern of antipsychotic use, and (2) the behavioural outcomes associated with their use. The dependent 
and independent variables included in the analyses and the statistical procedures used to answer the 
research questions are also described. All analyses were run on SAS for Windows version 9.1. 
4.1. Data Collection Tool: RAI 
The datasets were collected using the Resident Assessment Instrument (RAI) version 2.0 for long-term 
care facilities1. The RAI was developed by InterRAI, a non-profit international organization of 
researchers, to respond to the OBRA-87 which mandated its use in all US nursing homes primarily for 
care planning purposes, but also for research purposes, quality monitoring and benchmarking using a 
set of quality indicators, and for facility management and reimbursement using the case-mix algorithm 
(Morris et al., 1990). It was revised in 1994-95 (Version 2.0) and implemented across all US nursing 
homes in 1996.  
The Minimum Data Set (MDS), which is the core assessment tool of the RAI, is a 7-page 
questionnaire providing a standardized approach to assessing the health, functional and psychosocial 
needs and strengths of individuals living in long-term care facilities, such as nursing homes. More 
specifically, the MDS provides information on socio-demographic variables; cognitive patterns; 
communication, hearing and vision patterns; mood and behaviour patterns; psychosocial well-being; 
physical functioning and structural problems; bladder and bowel continence; disease diagnoses; health 
conditions; oral/nutritional and dental status; skin condition; activity pursuit pattern; medications; 
special treatments and procedures; and discharge potential and overall status. The full tool was designed 
 
1 For more information on the RAI instruments: www.interrai.org
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to be filled out by nursing staff within 14 days of admission to a facility, when significant change in 
resident function occurs, and annually after the admission date. A 5-page form, the Quarterly Review, 
contains a subset of key items and is designed to be used every 3 months after the full assessment. The 
Ontario full assessment tool is provided in Appendix C. 
The MDS also serves as a preliminary screening instrument to identify potential problems in 
resident’s status, through the Resident Assessment Protocols (RAP) (Morris et al., 1990). The RAPs 
function as decision facilitators, leading to a more thorough understanding of the problem and to the 
development of a sound care plan. The RAI 2.0 includes 18 RAPs, each outlining the problem of 
interest and the MDS trigger items, and providing a set of best practice guidelines. The RAP for 
Psychotropic Drug use, of particular interest in this study, was designed to flag potential side-effects or 
aggravation of existing symptoms and conditions for residents receiving antipsychotics, antidepressants 
or anxiolytics. Areas of concern are potential drug-related hypotension or gait disturbance, triggered by 
indicators such as repetitive physical movement and falls; potential drug-related cognitive and 
behavioural impairment, triggered by deterioration in cognitive status, mood and behavioural 
symptoms; and potential drug-related discomfort (see Appendix D for the RAP key). If any of these 
items is triggered, the RAP suggests reviewing the drug treatment, the resident’s condition that may 
impair drug metabolism and the behaviour, mood, and psychiatric status.  
The MDS has been well-established in the literature as a reliable and valid assessment tool (e.g. 
Hawes et al., 1990; Snowden et al., 1999). The MDS core set of items reach excellent reliability in 
areas of functional status, such as cognition, ADL, continence, and diagnoses (Snowden et al, 1999). 
The RAI instruments also reach high reliability coefficients across different countries, including Canada 
and Switzerland, establishing its utility for international comparison (Sgadari et al., 1997). Indeed, prior 
studies using the MDS to investigate international differences in nursing homes (e.g. Ribbe et al., 1997; 
Schroll et al., 1997) have shown that the MDS is a useful and valid tool. 
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4.2. Sample 
This study is based on two samples of nursing homes in two regions: the English-speaking province of 
Ontario in Canada and the German-speaking canton of Aargau in Switzerland. The sampling design is 
displayed in Appendix E. 
The Ontario nursing home data were derived from the pilot testing of the Canadian version of the 
MDS 2.0, as part of the RAI-Health Information Project (RAI-HIP) funded by a Health Transition Fund 
Grant from the Ministry of Health and Long Term Care. The cross-sectional sample comprised initial 
full assessments of 1961 individuals, collected between the period of December 1999 and February 
2001 in 24 nursing homes from different regions in Ontario. The sample was restricted to the initial 
1932 assessments with a valid entry for antipsychotic use. A subsample of 1540 residents were 
reassessed with the quarterly assessment  approximately 100 days after the initial assessment, with valid 
entry for antipsychotic use at time 1 (T1) and time 2 (T2).  This constituted the longitudinal sample in 
Ontario. 
The Swiss nursing home data were derived from the Swiss version of the MDS 2.0, collected 
routinely in nursing homes every 6 months. The Swiss cross-sectional sample was restricted to non-
admission assessments to reflect practice patterns of nursing homes. It comprised 1536 full 
assessments, collected between January 1999 and December 2002 in 4 nursing homes. The Swiss time 
frame was larger to increase sample size. If more than one assessment was available for a resident, the 
first one to appear in the dataset was chosen. Longitudinal data in Switzerland consisted of a subsample 
of 1175 residents who were reassessed approximately 156 days after the initial assessment, with valid 
entry for antipsychotic use at time 1 and time 2. Due to data protection regulations, resident’s date of 
birth and date of entry in nursing homes were not provided in the Swiss dataset. 
4.3. Patterns of Antipsychotic Use 
The dependent and independent variables and the analytic approach used to address the research 
questions pertaining to the first purpose of the study are described in this section. 
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4.3.1. Operational Definition of Variables 
The dependent variable is antipsychotic use. The independent variables were included for descriptive 
purpose and/or as possible correlates of antipsychotic use based on available literature. The 
corresponding item in the MDS is indicated in brackets for reference in the assessment form. 
Antipsychotic use
Antipsychotic use is recorded in the MDS 2.0 as the number of days the resident received antipsychotic 
medication within the last 7 days of assessment (O4a). Values range from 0 to 7, where 1 may represent 
long-acting medication used less than weekly. Since this study was interested in whether the resident is 
received antipsychotics or not, the variable was treated dichotomously: use (O4a≥1) or no use (O4a=0).  
Demographic variables
Age is computed in the MDS 2.0 by subtracting the date of birth (AA3a) from the date of assessment 
(A3) and dividing it by 365.25 to convert to years. Similarly, length of stay (LOS) is computed by 
subtracting the date of entry (AB1) from the date of assessment (A3) and dividing it by 365.25 to 
convert in years. Age and LOS are continuous variables, but were categorized for the multivariate 
analyses. Age and LOS were unavailable in the Swiss dataset. Gender (AA2) was also included for 
descriptive and analytic purposes.  
Diagnoses and health condition variables
Diagnoses and health conditions were of interest for descriptive purposes and as possible determinants 
of antipsychotic use. The neurological diagnoses of Alzheimer’s disease (I1q) and other types of 
dementia (I1u) were collapsed into one item. The following psychiatric/mood disorders were examined: 
anxiety disorder (I1dd), depression (I1ee), manic depressive (bipolar disorder) (I1ff), and schizophrenia 
(I1gg). Finally, symptoms of delusions (J1e) and hallucinations (J1i) were also included in the analyses. 
These items are all dichotomously coded in the MDS. 
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Behavioural variables
The MDS assesses behavioural symptoms by measuring the frequency of 5 types of behaviour within 
the last 7 days of assessment: wandering (E4aA), verbally abusive (E4bA), physically abusive (E4cA), 
socially inappropriate or disruptive (E4dA), and resisting care (uncooperativeness) (E4eA). These items 
are ordinal variables varying between 0 (behaviour not exhibited in last 7 days), 1 (behaviour occurred 
on 1 to 3 days in the last 7), 2 (behaviour occurred on 4 to 6 days in the last 7) and 3 (behaviour occurs 
daily). Since we were interested in whether the resident displayed the behaviour or not, all 5 variables 
were recoded dichotomously as behaviour not exhibited (0) or exhibited at least once within the last 7 
days (1).  
A summary measure of aggressive behaviour was also examined for descriptive purposes using 
the Aggressive Behaviour Scale (ABS) based on the addition of 4 behavioural items: verbally abusive, 
physically abusive, socially inappropriate, and resisting care behaviour. This scale measures the degree 
of severity of psychotic and behavioural problems, with scores ranging from 0 to 12. Those with the 
highest scores are residents who are verbally and physically abusive, socially inappropriate, and 
resisting care daily. Residents exhibiting at least one of the above behaviours, but less than daily, will 
have lower scores. The ABS was categorized into none (score of 0), mild (scores between 1 and 4) and 
severe (scores above 5) aggressive behaviour. This summary variable was not introduced in the 
multivariate model, as we were interested in identifying the type of behavioural symptoms for which 
antipsychotics were administered. 
The presence of repetitive physical movement such as restlessness and fidgeting within the last 
30 days of assessment (E1n), and the presence of insomnia or sleep disturbance within the last 30 days 
of assessment (E1k) were included in the analyses as a dichotomous variable. 
Social engagement and symptoms of depression were also included in the analyses. The Index of 
Social Engagement (ISE) is a summary measure of 6 items (F1a, F1b, F1c, F1d, F1e and F1f). The ISE 
ranges from 0 (no social engagement) to 6 (high level of social engagement) and has shown good inter-
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rater reliability (Sgadari et al., 1997).  This item was collapsed into no social engagement (score of 0), 
low (scores of 1 and 2) and high (scores between 3 and 6) levels of social engagement. This item is not 
present in the quarterly assessments. The Depression Rating Scale (DRS) measures depression 
symptoms, based on the sum of 7 items (E1a, E1d, E1f, E1h, E1l and E1m).  The scale ranges from 0 to 
14 and was categorized into no symptoms (score of 0), minor symptoms (scores of 1 and 2) and major 
symptoms (scores of 3 and above). Its' criterion validity was previously established in comparison to 
other scales (Burrows et al., 2000). 
Physical functioning variables
Physical functioning was measured with the embedded ADL Self-Performance Hierarchy (ADLH) 
scale. The ADLH measures residents’ stage of disablement based on four items treating early and later 
loss differently: early loss of personal hygiene (G1jA), middle loss of toileting and toilet use (G1iA), 
middle loss of movement and locomotion (G1eA) and late loss of eating (G1hA). The scale ranges from 
0 (independent) to 6 (total dependence) and has shown strong reliability (Morris, Fries & Morris, 1999; 
Canadian Collaborating Centre-InterRAI, 2003). It was categorized for the analyses into none (score of 
0), mild (scores of 1 and 2), moderate (scores of 3 and 4) and severe (scores of 5 and 6) impairment. 
Cognitive variables
Residents’ cognitive status was measured with the Cognitive Performance Scale (CPS). The CPS is 
computed with the addition of five items: whether the resident is comatose (B1), short term memory 
(B2a), cognitive skills for daily decision making (B4), ability to be understood by others (C4), and self-
performance in eating (G1hA) (Canadian Collaborating Centre-InterRAI, 2003). The CPS scores range 
from 0 (intact cognition) to 6 (very severe impairment). The CPS has been validated against the Mini-
Mental State Exam and the Test for Severe Impairment, and has shown strong reliability in nursing 
home populations (Morris et al., 1994; Hartmaier, Sloane, Guess & Koch, 1995; Gambassi et al, 2000). 
The CPS was categorized as none (score of 0), mild (scores of 1 and 2), moderate (score of 3), severe 
(scores of 4 and 5) and very severe impairment (score of 6).  
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Other medications, restraints and special care
Antianxiety drug use (O4b), antidepressant use (O4c), and hypnotic use (O4d) are coded in the MDS 
2.0 in the same manner as antipsychotic drugs and were treated dichotomously. Antianxiety and 
hypnotic drugs were collapsed, as the same medication (recorded according to the class in the MDS) 
can be used as anxiolytic or hypnotic.  
The MDS assesses restraint use with different categories: the use of bed rails (P4a and P4b) and 
chairs preventing rising (P4e), trunk (P4c) and limb restraint (P4c) within the last 7 days of assessment. 
These dichotomized variables were included for descriptive and analytic purposes. 
Whether the resident received a special symptom evaluation program in the last 7 days (P2a), and 
an evaluation by a licensed mental health specialist in the last 90 days (P2b) were included as potential 
determinants in the analyses. Whether the resident’s environment was changed to address mood or 
behaviour patterns - such as providing a room where to rummage – (P2d), and whether the resident was 
in an Alzheimer’s or dementia special care unit (P1aN) within the last 7 days of assessment were also 
included. These segregated units address the specific needs of cognitively impaired residents, who may 
or may not have a specific diagnosis of Alzheimer’s disease, in a supportive environment. 
Finally, the average case-mix index (CMI) was computed for descriptive purposes. The CMI is a 
summary measure associated with the RUG-III classification system of residents for funding purposes, 
based on clinical characteristics such as cognitive status, behaviour patterns, the amount of assistance 
required for activities of daily living (Fries et al., 1994). The CMI measures the relative utilization of 
care resources compared to a defined standard and provides an indication of required care. A higher 
average CMI would indicate a heavier case-mix of residents. The CMI system in Ontario (Hirdes, Botz, 
Kozak & Lepp,  1996) was applied to the Swiss dataset to allow international comparisons. 
30 
4.3.2. Cross-sectional Data Analyses 
The subsequent analyses were based on the cross-sectional samples. Longitudinal samples were used to 
compute incidence and cessation rates.  Datasets were assessed for missing values and coding errors. 
Question 1: What are the general characteristics of residents in Ontario and Switzerland? 
Univariate analyses (mean, standard deviation, N, frequency/proportions) were generated to describe 
the two samples separately on the following demographic and clinical characteristics: age, gender, and 
LOS; diagnoses and health conditions; behaviours characteristics; ADL and cognitive functioning; 
medications and restraint use; and special care. 
International comparison: Are there significant differences in the general characteristics of 
nursing home residents between Ontario and Switzerland? 
Each variable from question 1 was compared between the two samples to examine whether the 
differences in mean or proportion are statistically significant using the Student t-test for continuous 
variables and the chi-square (χ2) test for categorical variables.  
Question 2: What is the prevalence of antipsychotic use in Ontario and Switzerland among all 
residents and among residents with appropriate, potentially appropriate, and inappropriate 
indications?  
The prevalence of antipsychotic use in each dataset was computed by running frequency tables of 
antipsychotic use among all residents first: only including in the denominator residents with appropriate 
indications (schizophrenia and hallucinations); excluding from the denominator the residents with 
appropriate indications and only including the residents with potentially appropriate indications 
(dementia or cognitive impairment associated with being verbally abusive or physically abusive or 
socially inappropriate); and excluding from the denominator the residents with appropriate and 
potentially appropriate indications. These risk-adjusted prevalence rates were based on the criteria 
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defined by Zimmerman and colleagues (1995). Finally, the range of the rate of antipsychotic use by 
nursing homes within each country was computed.  
The initiation and cessation of antipsychotic use was also investigated for exploratory purposes, 
using the longitudinal sample. The proportion of individuals who initiated, stopped or continued taking 
antipsychotics between T1 and T2 was computed by running a frequency table between antipsychotic 
use at T1 and T2.  
International comparison: Is there a significant difference in the prevalence of antipsychotic 
use between Ontario and Switzerland? 
Chi square (χ2 ) tests were generated to assess differences between the two independent proportions of 
antipsychotic use, among all residents and for each denominator.  
Question 3: What are the determinants of antipsychotic use in Ontario and Switzerland? 
Bivariate and multivariate analyses were performed to examine what characteristics determined 
antipsychotic use in the two samples separately. Bivariate analyses were carried out to determine 
variables to be included in multivariate analyses. The association between antipsychotic use and all 
categorical independent variables were assessed with the chi-square statistic. Crude odds ratios were 
also generated. Logistic regression analysis was then performed by running the full model with all 
variables and selecting the best-fitted model through backward selection procedure. The final model 
included variables with significant regression coefficients at the 0.05 level or deemed to be important to 
warrant goodness-of-fit. Interaction terms were created, introduced in the model and retained if 
significant. Finally, adjusted odds ratios were computed.  
International comparison: Do the determinants differ between Ontario and Switzerland? 
The two equations were compared without running statistical tests. 
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4.4. Behavioural Outcomes of Antipsychotic Use 
The dependent and independent variables and the analytic approach to address the research questions 
pertaining to the second purpose of the study are described in this section.  
4.4.1. Operational Definition of Longitudinal Variables 
Twenty-four situations of change in resident behaviour were investigated as outcome variables in each 
sample separately, resulting in 24 models with 24 different dependent variables. Residents who did not 
change were not of primary interest in this study. 
First, the initiation and cessation of the 5 behavioural symptoms – wandering, verbally abusive, 
physically abusive, socially inappropriate, and resisting care – and the initiation and cessation of 
aggressive behaviour in general were investigated as 12 separate outcome variables. Residents initiated 
the behaviour of interest when they displayed the behaviour at T2 but not at T1 and stopped the 
behaviour of interest when they displayed the behaviour at T1 but not at T2.  
Second, the improvement and deterioration of the 5 behaviours listed above and aggressive 
behaviour in general were explored as 12 other outcome variables. Residents improved in the behaviour 
of interest when they displayed the behaviour less frequently at T2 than at T1. Residents deteriorated in 
the behaviour of interest when they displayed the behaviour more frequently at T2 than at T1. 
Antipsychotic use at T1 was the primary independent variable of interest, as the study’s aim was 
to investigate behavioural changes associated with their use. In order to ensure that behavioural changes 
were not due to changes in antipsychotic use, residents who initiated or stopped receiving antipsychotic 
at T2 were excluded from the bivariate and multivariate analyses. 
The following risk factors for disruptive behaviours measured at T1 were considered as potential 
confounding variables for all predicting models: gender, age and LOS (for Ontario only); behaviours 
(wandering, verbally abusive, physically abusive, socially inappropriate and resisting care); depression 
measured with the categorized DRS; social engagement measured with the categorized ISE; physical 
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functioning measured with the ADLH scale categorized into mild (0-2), moderate (3-4) and severe (5-6) 
impairment; cognition measured with CPS and categorized as mild (0-1), moderate (2-3), and severe (4-
6) cognitive impairment; several diagnoses (dementia, anxiety disorder, depression) and the number of 
active diagnoses; delusions and hallucinations; incontinence (bowel and bladder); medications 
(antianxiety, antidepressant, hypnotic) and number of medications received; and restraints (full bed rail, 
half bed rail, trunk, chair). Pain was also included measured with the embedded pain scale. It ranges 
from 0 to 3 and was categorized into no pain (0), mild pain (1), and severe pain (2 and 3). Finally, 
whether the resident received a behaviour intervention (item P2a, P2b and P2d) was also included. 
4.4.2. Longitudinal Data Analyses 
The subsequent analyses were based on the longitudinal samples. The analytic approach is presented for 
the two research questions combined. The two datasets were not collapsed for the investigation of 
outcomes because of the large differences in resident characteristics. 
Question 5 and 6: Does antipsychotic use predict the initiation, the cessation, the improvement and/or 
the cessation of the following behaviours: wandering, verbally abusive, physically abusive, socially 
inappropriate, resisting care, and aggressive behaviour? 
Descriptive statistics were conducted first to determine the proportion of residents who initiated and 
stopped displaying the behaviour, and the proportion of residents who improved, did not change, and 
deteriorated in the behaviour of interest.  
Residents displaying the behaviour of interest at T1 were excluded from the sample for incidence 
models, whereas only residents displaying the behaviour of interest at T1 were included in the sample 
for the cessation model. Consequently, the sample size for incidence models was larger than for 















The baseline sample for the improvement and deterioration models consisted of residents 
displaying the behaviour at T1.Residents not displaying the behaviour at baseline were excluded. The 











Associations between the change in behaviour and antipsychotic use were assessed using the chi-square 
statistic. Only antipsychotic users at both times and non-users at both times were included in the 
sample. If antipsychotic use was associated with a behavioural change, the association between the 
change in behaviour and other confounding variables were investigated in bivariate analyses. Finally, 
logistic regression was conducted including antipsychotic use and other risk factors associated in 
bivariate analyses to predict behavioural change. Logistic regression was chosen as analytic method 
over Generalized Estimated Equations (GEE) method (used for data with repeated measures per 
subject) because computing change as the difference in scores resulted in an outcome variable that was 
no longer measured repeatedly.  Also, the independent variables that were included in the model were 
only measured at T1.  
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5. CROSS-SECTIONAL RESULTS 
The results on general characteristics are based on the full cross-sectional samples from nursing homes 
in Ontario (n=1961) and in Switzerland (n=1536). The results on the prevalence of antipsychotic use 
and characteristics associated with antipsychotic use are based on the Ontario sample with valid entry 
for antipsychotic use (n=1932) and the full Swiss sample (n=1536). 
5.1. Resident Characteristics 
Tables 1 and 2 present the general characteristics of the nursing home population in Ontario and 
Switzerland. Most characteristics differed at the 0.05 level in the international comparisons. 
With regards to demographic variables, most residents were female in both samples. However, 
the sample in Ontario comprised a higher proportion of females (74%) than in Switzerland (64%) 
(p<.0001). In Ontario, the average age was 82.5 years and almost half the sample was over 85 years old. 
The average length of stay was 3 years and 10 months, and almost a third of the sample was in the 
nursing home for less than a year. The mean age and length of stay could not be computed in the 
Switzerland sample as these variables were unavailable. The case-mix index (CMI), based on the 
Ontario calculation, was lower in the Swiss sample than in Ontario (p<.0001). 
Residents in Ontario were more cognitively impaired with a mean score of 3.13 compared to 2.76 
in Switzerland (p<.0001), and more impaired in ADL with a mean score of 3.53 compared to 3.06 in 
Switzerland (p<.0001). Nursing homes in Ontario had a higher proportion of residents suffering from 
dementia (53%) than Switzerland (21%) (p<.0001). However, the proportion of residents in a dementia 
special care unit was similar (~9 %). A significantly higher proportion of residents received a behaviour 
symptom program and an evaluation by mental health specialist in Ontario than in Switzerland, while 
the environment was changed to address mood or behaviour problems for the same proportion of 
residents. A much higher proportion of residents had more than 5 diagnoses in the Ontario sample 
(p<.0001). Finally, Swiss residents had significantly lower levels of social engagement. 
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The distribution of psychiatric disorders was quite different. A higher proportion of Ontario 
residents suffered from anxiety disorder and schizophrenia compared to Swiss residents (p<.0001). The 
prevalence rates of depression, bipolar disorder, delusions and hallucinations were slightly higher in the 
Ontario sample than in the Swiss one, while the rate of depressive symptoms was similar and the rate of 
insomnia was slightly higher in the Swiss sample.  
More residents in Ontario displayed wandering behaviour than in Switzerland, while the pattern 
of restless behaviour tended to be similar. Aggressive behaviours –verbally abusive, physically abusive, 
socially inappropriate and resisting care – were significantly more prevalent in the Ontario sample than 
in the Swiss one.  Further, the rate of physically abusive and resisting care behaviour in the Ontario 
sample was twice the rate in the Swiss one. Thus, the mean score on the ABS was significantly higher 
in Ontario (2.41) than in Switzerland (1.17). Indeed, 37% of the residents in Switzerland exhibited at 
least one aggressive behaviour compared to 55% in Ontario, and only 12% exhibited severe aggressive 
behaviour compared to 26% in Ontario.  
The proportion of residents receiving anxiolytics/hypnotics medications was similar (~24%), 
though most drugs were recorded as anxiolytics in Ontario and as hypnotics in Switzerland. The 
proportion of residents receiving antidepressants was similar (~29%). Finally, the use of full and half 
bed rails and chairs preventing rising was much more prevalent in Ontario than in Switzerland. The use 
of trunk restraint was low in both samples.  
Table 1. Comparison of the mean of continuous variables in Ontario and in Switzerland1
Ontario Switzerland 
Variable N mean SD N Mean SD p-valuea
Age (yrs) 1960 82.53 9.78 not available  
LOS (yrs) 1949 3.86 5.32 not available  
CPS (0-6) 1961 3.13 2.07 1536 2.76 1.95 <.0001 
ADL (0-6) 1956 3.53 1.82 1536 3.06 1.87 <.0001 
ABS (0-12) 1956 2.41 3.14 1536 1.17 2.14 <.0001 
CMI (0.46-1.63) 1961 0.75 0.19 1525 0.70 0.20 <.0001 
a = p-value associated with t-test for differences in mean between 2 independent samples 
 
1 For all tables, abbreviations were used as follows: AP=Antipsychotic, ABS=Aggressive Behaviour Scale, AD=Alzheimer’s 
disease, ADL=Activities of Daily Living, CMI=Case Mix Index, CPS=Cognitive Performance Scale, DRS=Depression Rating 
Scale, LOS=Length Of Stay, MH=Mental Health, OR=Odds Ratio, CI=Confidence Interval, SD=Standard Deviation, 
SE=Standard Error 
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a = p-value associated with chi-square test for differences in proportions between 2 independent samples 
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Table 2. Comparison of the frequency and distribution of categorical variables in Ontario and in 
Switzerland (continued) 
Ontario Switzerland 





Low level 1-2 



























































Mood and behaviour intervention 
Behaviour symptom eval. prog. 
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a = p-value associated with chi-square test for differences in proportions between 2 independent samples 
5.2. Prevalence of Antipsychotic Use 
Table 3 presents the distribution of antipsychotic administration within the last 7 days of assessment in 
the 2 samples. In both settings, antipsychotics were mostly administered on a daily basis. The 
aggregated pattern of antipsychotic administration was significantly different and indicated that 29.5% 
of the Swiss sample received antipsychotics versus 25% of the Ontario sample. 
Table 3. Comparison of the prevalence of antipsychotic use in Ontario and in Switzerland 
Ontario (N = 1932) Switzerland (N = 1536) # of days of antipsychotic 





























































a = p-value associated with chi-square test for differences in proportions between 2 independent samples 
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When examining the use of antipsychotics by nursing homes in Switzerland, the prevalence rate 
varied from 23% (nursing home #1) to 34% (nursing home #2) (p<.0.01). The rate varied even more 
between nursing homes in the Ontario dataset, from 12% to 47% (p<.0001). However, the number of 
assessments per nursing home varied greatly as well, limiting the validity of this relationship. 
Table 4 presents the prevalence of antipsychotics by appropriateness of use. Antipsychotics were 
prescribed to 62% and 65% of the residents with conditions appropriate for antipsychotic prescription in 
a similar pattern in the Ontario and Swiss sample respectively. Among potentially appropriate residents, 
the proportion of users was larger in Switzerland (42%) than in Ontario (37%), though the difference 
was not significant (p=0.1616). However, among potentially inappropriate residents, the proportion of 
users was significantly higher in Switzerland (24.5%) than in Ontario (14%) (p <.0001).  
Table 4. Comparison of the prevalence of antipsychotic use by appropriateness in Ontario and 
Switzerland 
Ontario Switzerland 








Appropriatea 150 93 62.00 55 36 65.45 
Potentially appropriateb 568 211 37.15 337 141 41.84 
Potentially inappropriatec 1128 157 13.92 1122 275 24.51‡ 
Totald 1912* 479 25.05 1514 452 29.85† 
Note: appropriateness based on criteria defined by Zimmerman et al. (1995). See section 2.3.2 for further details. 
a Residents with schizophrenia or hallucinations. 
b Residents with dementia or cognitive impairment, associated with being verbally or physically abusive or socially 
inappropriate. Appropriate residents excluded. 
c Appropriate and potentially appropriate residents excluded. 
d Residents with end-stage disease and in hospice care excluded from all analyses. 
*The total differs from the addition of the 3 categories due to missing variables 
† p <.005 ‡ p <.0001 
 
Figure 1 displays the distribution of appropriateness among antipsychotic users separately in the 
two countries. In Ontario, 20% of users had an appropriate condition, 46% had potentially appropriate 
conditions, and 34% had potentially inappropriate conditions. In Switzerland, less than 10% of users 
had appropriate conditions, 31% had potentially appropriate conditions, and 61% of users had 
potentially inappropriate indications.  
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Figure 1. Distribution of appropriateness among antipsychotics users in Ontario and Switzerland 













5.2.1. Cross-sectional Time Series of Antipsychotic Use in Switzerland 
The time-frame of the Swiss dataset allowed for further analysis of the pattern of antipsychotic use 
based on the entire Swiss dataset (assessments from 1997 to 2005), described in tables 1 and 2 in 
Appendix F. The prevalence of antipsychotic administration was examined by fiscal year of assessment. 
Figure 2 presents the rate of antipsychotic administration for newly admitted residents (based on 
admission assessments completed within 14 days of entry), existing residents (based on non-admission 
assessments) and all residents, by year. The rate of antipsychotic administration for new residents was 
lower than the rate in existing residents for each year. Both rates increased over time, with a peak in 
2004 where 37% of new residents and 43% of existing residents were administered antipsychotics 
(range by nursing home: 33% to 49%). The rate in existing residents decreased slightly in 2005, while 
the rate in new residents dropped to 25% in 2005.  
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The prevalence rate of antipsychotic use at admission for short stay residents, who were 
discharged before a second assessment (stay under 5 months), was lower than for long stay residents, 
who remained in a nursing home at least until second assessment (stay over 5 months), as shown in 
figure 3. The rate at admission for short stay residents increased slightly over time, whereas the rate for 
long stay residents increased considerably, especially between 2002 and 2003. 
Figure 3. Prevalence of antipsychotic use at admission assessment for short stay and long stay 
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AP use at admission for long stay residents
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5.3. Characteristics Associated with Antipsychotic Use 
5.3.1. Bivariate Analyses 
Table 5 displays the prevalence of antipsychotic use by demographic variables, as well as crude odds 
ratios - unadjusted for other independent variables - with p-values associated with the chi-square test 
from bivariate analyses in the Ontario and Swiss samples separately. Gender was not associated with 
antipsychotic use, though it was more prevalent among males than females in both samples. Age was 
significantly associated with antipsychotic use in Ontario (p=.0004) as residents over 85 years old were 
two times less likely to receive antipsychotics compared to residents under 65. In the Ontario sample, 
the relationship between antipsychotic use and categories of length of stay was U-shaped (p=0.0062), 
where the prevalence rates among residents with shorter (<1 yr) and longer (5+ yrs) stays were higher 
than residents with lengths of stay between 1 and 5 years.  
Table 5. Prevalence of antipsychotic use by demographic variables, crude OR and 95% CI, and p-
values from bivariate analyses in Ontario and Switzerland 
Ontario Switzerland 
Variable AP use 
(%) 
































































a: reference category 
 
Table 6 presents the prevalence of antipsychotic use by clinical and behavioural characteristics as 
well as crude odds ratios with p-values associated with the chi-square test from bivariate analyses in the 
Ontario and Swiss samples separately. In both settings, dementia was significantly associated with 
receiving antipsychotics, especially in Switzerland where residents suffering from dementia were 
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almost three times more likely to receive antipsychotics. The prevalence of antipsychotic use was 
significantly higher among residents with anxiety disorder in the Ontario sample (p<.0001). Cases of 
anxiety disorders in the Swiss dataset were insufficient to make any inferences. Suffering from bipolar 
disorder, schizophrenia, delusions and hallucinations were all significantly associated with receiving 
antipsychotics in both samples.  
In Ontario and Switzerland, residents displaying wandering behaviour, being verbally abusive, 
physically abusive, socially inappropriate, resisting care, and being restless were all significantly more 
likely to receive antipsychotics than those without these symptoms. Suffering from insomnia was 
significantly associated with receiving antipsychotics in both samples (p<.0001). In Ontario, residents 
with higher levels of social engagement had a significantly lower prevalence rate than residents less 
involved. The relationship was not significant in Switzerland, though residents highly involved had 
lower rates of antipsychotic use. A diagnosis of depression was not associated with antipsychotics in the 
Ontario sample (p=.1212), while mildly associated in the Swiss sample (p=.0838). However, when 
measuring depression using the DRS, the relationship became significant in both samples (p<.0001): 
residents suffering from depression were more likely to receive antipsychotics. Finally, in both samples, 
the rate of antipsychotic use was higher among residents with physical impairment compared to 
residents with no impairment, especially for residents with mild and moderate physical impairment. 
The prevalence rates of antipsychotic use among residents receiving antianxiety or hypnotic 
drugs, and antidepressants were higher than those not receiving these drugs in both samples, but the 
relationships were only significant in the Ontario sample. In Ontario, residents with full bed rails were 
significantly less likely to receive antipsychotics. On the other hand, residents with half bed rails and 
chairs preventing rising had a higher prevalence rate of antipsychotic use. In Switzerland, residents with 
half bed rails had greater odds of receiving antipsychotics. Trunk restraint was not associated with 
receiving antipsychotics in either country. In both settings, residents who received environmental 
changes and were in a dementia special care unit were significantly more likely to receive 
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antipsychotics than residents not receiving those types of care (p<.0001). In Ontario, an evaluation by a 
mental health specialist was also associated with receiving antipsychotics. 
Table 6. Prevalence of antipsychotic use by clinical and behavioural variables, with crude OR, 






















































































































































































































































































Table 6. Prevalence of antipsychotic use by clinical and behavioural variables, with crude OR, 
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As shown in figure 4, greater cognitive impairment was significantly associated with greater 
prevalence rates of antipsychotic use in both samples (p<.0001 in Ontario Switzerland), while the 
prevalence rate decreased among residents with very severe cognitive impairment.  













AP use in Ontario AP use in Switzerland
 
5.3.2. Multivariate Analyses 
Table 7 displays the results of logistic regression analyses examining characteristics independently 
associated with the use of antipsychotics in the Ontario and Swiss sample separately. Variables that 
failed to reach significance were excluded to produce a more parsimonious and better fitting model. In 
the Ontario sample, 16 variables were included in the multivariate model and 14 variables were 
statistically significant at the 0.05 level. In the Swiss sample, 10 variables were included in the model 
and 8 were statistically significant at the 0.05 level.  
Four factors were found to be common determinants in the two samples. The psychiatric 
diagnoses of schizophrenia and bipolar disorder were the strongest determinants of antipsychotic use in 
the two datasets. Cognitive impairment was also among the most significant factors linked to 
antipsychotic use in the two samples. Cognitively impaired resident were between 1.7 and 2.8 times 
more likely to receive antipsychotics. Finally, dementia was a significant determinant in the Swiss 
sample (OR=2.18, CI 1.64-2.9), while mildly associated with antipsychotic use in the Ontario sample 
(OR=1.32, CI 0.97-1.81). All other factors differed between the two samples. 
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In the Ontario sample, residents with symptoms of depression (measured with the DRS) were 
almost three times more likely to be administered antipsychotics compared to non-depressed residents. 
Residents displaying wandering (OR=1.47, CI 1.07-2.04), physically abusive (OR=1.87, CI 1.36-2.56) 
and inappropriate behaviours (OR=1.46, CI 1.08-1.96) were more likely to receive antipsychotics then 
those without these behavioural symptoms. Having an anxiety disorder (OR=1.75, CI 1.06-2.90), as 
well as receiving anxiolytics or hypnotics (OR=1.52, CI 1.14-2.03), was associated with receiving 
antipsychotics. Residents who were in a dementia care unit (OR=1.69, CI 1.14-2.51) and who received 
an evaluation by a mental health specialist (OR=2.43, CI 1.32-4.65) had greater odds of receiving 
antipsychotics compared to residents not receiving such care.  Residents with full bed rails were less 
likely to receive antipsychotics (OR=0.74, CI 0.54-1.00).  By contrast, residents with chairs preventing 
rising were more likely to receive antipsychotics (OR=1.38, CI 1.00-1.91). Finally, age and a length of 
stay between 1 and 5 years were inversely associated with antipsychotic use. For instance, the odds of 
receiving antipsychotics for residents under 65 were twice the odds of residents over 85.  
In the Swiss dataset, delusions (OR=2.49, CI 1.31-4.71), restlessness (OR=2.36, CI 1.78-3.13), 
insomnia (OR=1.51, CI 1.10-2.06), half bed rails (OR=1.51, CI 1.13-2.02), and being in the nursing 
home #2 (OR=1.45, CI 1.01-2.08) were significant determinants for antipsychotic use. ADL 
impairment was the only protective factor against antipsychotic use, as residents severely impaired in 
ADL were less likely to receive antipsychotics compared to residents not impaired. Finally, neither 
specific behavioural variables nor aggressive behaviour were statistically significant determinants for 
antipsychotic use.  
Gender did not emerge as a statistically significant determinant in either dataset neither did 
hallucinations, verbally abusive and resisting care behaviours, the diagnosis of depression and 
antidepressant use.  
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Table 7. Characteristics concurrently associated with antipsychotic use: results of logistic 
regression analysis in Ontario and Switzerland 




















Intercept -2.41 (0.36)   -2.13 (0.25)   
Bipolar disorder 2.17 (0.44) <.0001 8.76 (3.68-20.84) 1.25 (0.50) 0.0126 3.49 (1.31-9.31) 
Schizophrenia 2.67 (0.28) <.0001 14.47 (8.35-25.05) 2.15 (0.48) <.0001 8.55 (3.32-21.99) 
CPS 
- Mild vs none  
- Moderate vs none 
- Severe vs none 































Dementia 0.28 (0.16) 0.0835 1.32 (0.97-1.81) 0.78 (0.14) <.0001 2.18 (1.64-2.90) 
Dementia unit 0.53 (0.20) 0.0090 1.69 (1.14-2.51) not significant 
MH specialist 0.91 (0.32) 0.0047 2.43 (1.32-4.65) not significant 
DRS  
- Minor vs none  











not significant  
Anxiety disorder 0.56 (0.26) 0.0278 1.75 (1.06-2.90) not significant 
Wandering  0.39 (0.17) 0.0190 1.47 (1.07-2.04) not significant 
Physically abusive 0.62 (0.16) 0.0001 1.87 (1.36-2.56) not significant 
Soc. inappropriate 0.38 (0.15) 0.0128 1.46 (1.08-1.96) not significant 
Anxiolytic/hypnotic 0.42 (0.15) 0.0068 1.52 (1.14-2.03) not significant 
Full bed rail -0.31 (0.15) 0.0479 0.74 (0.54-1.00) not significant 
Chair 0.32 (0.17) 0.0532 1.38 (1.00-1.91) not significant 
Age 
- 65-75 vs <65 
- 75-85 vs <65 
















- 1-3yrs vs <1yr  












Delusions not significant 0.91 (0.33) 0.0053 2.49 (1.31-4.71) 
Restlessness not significant 0.86 (0.14) <.0001 2.36 (1.78-3.13) 
Insomnia not significant 0.41 (0.16) 0.0105 1.51 (1.10-2.06) 
ADL 
- mild vs none  
- moderate vs none  















Half bed rail not significant 0.41 (0.15) 0.0049 1.51 (1.13-2.02) 
Facility-Switzerland 
- #2 vs #1  
- #3 vs #1 

















LR χ2=421, df=24, p<.0001 
C statistic: 0.8    Hosmer-Lemeshow: p=0.57
LR χ2=236, df=14, p<.0001 
C statistic: 0.74    Hosmer-Lemeshow: p=0.33 
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6. LONGITUDINAL RESULTS 
The longitudinal results are based on the longitudinal samples in Ontario (n=1540) and Switzerland 
(n=1175). Time 1 (T1) assessment refers to resident’s initial assessment (but not the admission 
assessment) and time 2 (T2) assessment refers to resident’s second assessment, on average 3 months 
later in the Ontario sample and 5 months later in the Swiss sample. General characteristics of the 
Ontario and Swiss longitudinal subsample did not differ significantly from the characteristics of the 
cross-sectional sample.  
6.1. Longitudinal Pattern of Antipsychotic Use 
Table 8 presents the distribution of antipsychotic use at T1 and T2 in the Ontario and Swiss longitudinal 
samples. In Ontario, the rate remained similar, whereas the Swiss rate increased from 30% to 33%. 
Antipsychotic use was more prevalent at both times in Switzerland than in Ontario.  
Table 8. Prevalence of antipsychotic use at T1 and T2 in Ontario and Switzerland 
 Ontario Switzerland 
T1 T2 (~3 months later) T1 T2 (~5 months later) 




























Figure 5 displays the change in antipsychotic use between T1 and T2 in Ontario and Switzerland. 
Most residents either stayed on antipsychotics or remained free of antipsychotics at both times in the 
two samples, and few residents stopped or initiated antipsychotics. Nevertheless, more change occurred 
in the Swiss sample than in the Ontario sample. For instance, the initiation rate in Switzerland (12%) 
was higher than in Ontario (5%). 
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T1 T2 (~3 months later) T1 T2 (~5 months later) 
AP users 
n = 372
AP users  
n = 328




AP users  
n = 296




AP users  
n = 55




AP users  
n = 97
AP non-users  
n = 720
6.1.1. Antipsychotic Use at Admission and Reassessment by Year in 
Switzerland 
The time-frame of the Swiss dataset allowed for the analysis of the longitudinal pattern of antipsychotic 
administration at admission and at reassessment by year. This is displayed in figure 6 for residents with 
at least two assessments. Overall, the rate of antipsychotic use at reassessment was higher than the rate 
at admission. The rate among residents assessed at two times was especially high in 2003 and 2004, 
where almost half of the residents were administered antipsychotics at admission and reassessment. 
Figure 6. Prevalence of antipsychotic use at admission and at reassessment for residents with at 
























6.2. Longitudinal Patterns of Behavioural Symptoms 
Table 9 presents the prevalence of behaviours of interest at T1 and T2 in the Ontario and Swiss 
longitudinal samples. In Ontario, the prevalence rates of all the behaviours of interest increased slightly 
at T2. In Switzerland, the rate of wandering decreased at T2, while it increased for the other behaviours 
of interest. The details of behavioural changes can be found in Appendix G. 
Table 9. Prevalence of behaviours at T1 and T2 in Ontario and Switzerland 
 Ontario Switzerland 
T1 T2  
(~3 months later) 
T1 T2  
(~5 months later) 
Behaviour of interest Freq. Percent Freq. Percent Freq. Percent Freq. Percent 
Wandering 310 20.33 328 21.51 214 18.21 195 16.60 
Verbally abusive 427 28.11 478 31.47 318 27.06 348 29.62 
Physically abusive 284 18.65 296 19.44 117 9.96 131 11.15 
Socially inappropriate 414 27.13 435 28.51 188 16.00 206 17.53 
Resisting care 653 42.88 687 45.11 220 18.72 247 21.01 
Aggressive behaviour 850 55.19 891 57.86 461 39.23 494 42.04 
6.2.1. Behavioural Initiation and Cessation 
The frequency and percentage of residents who started (initiation) and stopped (cessation) displaying 
the behaviour of interest between T1 and T2 are presented in tables 10 and 11. In general, the number of 
residents starting displaying the behaviour was higher than the number of residents stopping in both 
samples, explaining the increase in overall prevalence.  
Apart from aggressive behaviour in general, the highest initiation rate was for resisting care 
behaviour in Ontario and verbally abusive behaviour in Switzerland. The initiation rates were slightly 
higher in the Ontario sample than in the Swiss samples for all behaviours except verbal abuse.  
Table 10. Initiation of behaviours of interest between T1 and T2 in Ontario and Switzerland: 
frequencies and percentages  
Ontario Switzerland 
Initiation of behaviour N baseline* Freq. Percent N baseline* Freq. Percent 
Wandering 1241 58 4.77 961 39 4.06 
Verb. abusive  1092 101 9.25 857 97 11.32 
Phys. abusive  1239 70 5.65 1058 42 3.97 
Soc. inappropriate  1112 94 8.45 987 61 6.18 
Resisting care  870 109 12.53 955 73 7.64 
Aggressive  673 116 17.24 714 113 15.83 
*number of residents not displaying the behaviour of interest at T1 
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The highest cessation rate was for physically abusive behaviour in Ontario and for wandering 
behaviour in Switzerland. The cessation rates for all six behaviours were higher in the Swiss sample 
compared to the Ontario one. 
Table 11. Cessation of behaviours of interest between T1 and T2 in Ontario and Switzerland: 
frequencies and percentages 
Ontario Switzerland 
Cessation of behaviour N baseline* Freq. Percent N baseline* Freq. Percent 
Wandering 310 40 12.90 214 58 27.10 
Verbally abusive  427 50 11.71 318 67 21.07 
Physically abusive  284 58 20.42 117 28 23.93 
Socially inappropriate  414 73 17.63 188 43 22.87 
Resisting care  653 75 11.48 220 46 20.91 
Aggressive  841 77 9.16 461 80 17.35 
*number of residents displaying the behaviour of interest at T1 
6.2.2. Behavioural Improvement and Deterioration 
Figure 7 and 8 presents the percentage of residents who improved, did not change, and deteriorated 
their behaviour between T1 and T2 (for each behaviour of interest separately) in Ontario and 
Switzerland respectively. While most residents displayed the same frequency of behavioural symptoms 
at both times, the proportion of residents who improved in their behavioural symptoms was greater than 
the proportion of residents who deteriorated in both samples.  
In Ontario (figure 7), improvement rates for separate behaviours were fairly similar (~20%) 
except for the improvement rate for physically abusive behaviour (32%). Deterioration rates were fairly 
similar as well (~9%) except for the deterioration rate of physically abusive behaviour (15%). For 
aggressive behaviour in general, approximately the same number of aggressive residents improved and 
deteriorated (~25%). 
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Figure 7. Change in behaviour between T1 and T2 among residents displaying the behaviour of 






















In Switzerland (figure 8), improvement rates for separate behaviours ranged from 30% to 35%, while 
deterioration rates ranged from 9% to 13%. The deterioration rate for aggressive behaviour in general 
was the highest (25%). 
Figure 8. Change in behaviour between T1 and T2 among residents displaying the behaviour of 






















The improvement rates for all behaviours were higher in the Swiss sample compared to the Ontario 
sample. Deterioration rates were similar, although a higher proportion of Swiss residents with verbally 
abusive and socially inappropriate behaviour deteriorated compared to residents in Ontario. 
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6.3. Antipsychotic Use and Behavioural Change 
6.3.1. Bivariate Analyses I: Antipsychotic Use and Behavioural 
Initiation/Cessation  
The rates of initiation/cessation among antipsychotic users and non-users are presented in tables 12 and 
13, as well as crude odds ratios for the association between antipsychotics and behaviour change. 
Residents who stopped or started using antipsychotics between T1 and T2 were excluded. 
Behavioural initiation
Overall, the initiation rates for all behaviours were higher among antipsychotic users than non-users in 
both samples. However, the relationship between initiation and antipsychotic use was not statistically 
significant in all cases. In the Ontario sample, antipsychotic users were significantly more likely to start 
wandering, and being verbally abusive and socially inappropriate than non-users. In the Swiss sample, 
the odds of antipsychotics users to initiate physically abusive, socially inappropriate and aggressive 
behaviours were significantly higher than the odds of non-users, while the relationship between 
antipsychotic use and being verbally abusive was statistically significant at the 0.1 level of significance. 
Table 12. Relationship between initiation of behaviour and antipsychotic use in Ontario: 
frequencies and percentages among AP users and non-users, and crude OR and 95% CI 
Ontario Switzerland 
AP user AP non-user AP user AP non-user Initiation of 
behaviour Freqa % Freqb %
Crude OR



































































6.39 1.57  
(0.90-2.73) 












*p <.10, **p <.05, ***p <.005 
a: baseline samples were residents receiving antipsychotics and not displaying the behaviour of interest at T1 (in brackets) 
b: baseline samples were residents not receiving antipsychotics and not displaying the behaviour of interest at T1 (in brackets) 
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Behavioural cessation
The cessation rates for all behaviours were lower among antipsychotic users compared to non-users in 
Ontario. However, antipsychotic use was only statistically associated with the cessation of three 
behaviours: physically abusive (p<0.05), verbally abusive (p<0.1), and aggressive behaviour (p<0.05).  
In the Swiss sample, the cessation rates for wandering, verbally abusive, socially inappropriate 
and aggressive behaviours were lower among antipsychotic users compared to non-users. On the other 
hand, a higher proportion of users stopped being physically abusive and resisting care. However, the 
association was not statistically significant in most cases. Antipsychotic users were less likely to stop 
displaying wandering (p<0.05) and socially inappropriate behaviour (p<0.1) compared to non-users. 
Table 13. Relationship between cessation of behaviour and antipsychotic use in Switzerland: 
frequencies and percentages among AP users and non-users, and crude OR and 95% CI 
Ontario Switzerland 
AP user  AP non-user AP user AP non-user Cessation of 
behaviour Freqa % Freqb %
Crude OR 



































































19.09 1.34  
(0.66-2.70) 










16.59 0.75  
(0.42-1.34) 
*p <.10, **p <.05, ***p <.005 
a: baseline samples were residents receiving antipsychotics and displaying the behaviour of interest at T1 (in brackets) 
b: baseline samples were residents not receiving antipsychotics and displaying the behaviour of interest at T1 (in brackets) 
6.3.2. Bivariate Analyses II: Antipsychotic Use and Behavioural 
Improvement/Deterioration 
The rates of behavioural improvement and deterioration among antipsychotic users and non-users are 
presented for each country separately in tables 14 and 15, as well as the crude odds ratio for the 
relationship between antipsychotic use and change in behaviour. Among antipsychotic users, a higher 
56 
proportion improved their behaviour than deteriorated in both samples. When considering aggressive 
behaviour in general, more antipsychotic users deteriorated than improved in Ontario, while slightly 
more users improved than deteriorated in Switzerland.  
Behavioural improvement
Overall, less antipsychotic users improved their behaviour compared to non-users in Ontario. However, 
antipsychotic use was inversely associated with the improvement of three behaviours at the 0.1 level of 
significance. Antipsychotic users were less likely to improve their resisting care behaviour (p<0.05), 
and verbally and physically abusive behaviour (p<0.1) compared to non-users.  
In the Swiss sample, the improvement rates for wandering, verbally abusive, socially 
inappropriate and aggressive behaviours were lower among antipsychotic users compared to non-users, 
while higher for physically abusive and resisting care behaviours. However, antipsychotic use was only 
statistically associated with the improvement of two behaviours. Antipsychotic users were less likely to 
improve their wandering and socially inappropriate behaviour (p<0.05) compared to non-users.   
Table 14. Relationship between improvement of behaviour and antipsychotic use in Ontario and 
Switzerland: frequencies and percentages among AP users and non-users, and crude OR 
Ontario Switzerland 
AP usera AP non-userb AP usera AP non-userb
Improvement of 
behaviour Freq % Freq
 %
Crude OR













































































*p <.10, **p <.05, ***p <.005  
a: baseline samples were residents receiving antipsychotics and displaying the behaviour of interest at T1 (in brackets) 
b: baseline samples were residents not receiving antipsychotics and displaying the behaviour of interest at T1 (in brackets) 
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Behavioural deterioration
Overall, a higher proportion of antipsychotic users deteriorated their behaviour compared to non-users 
in both samples for all behaviours. In the Ontario sample, only the odds of antipsychotics users to 
deteriorate in aggressive behaviour were significantly higher than the odds of non-users. Antipsychotic 
use was not statistically associated with any behavioural deterioration in the Swiss sample.  
Table 15. Relationship between deterioration of behaviour and antipsychotic use in Ontario and 
Switzerland: frequencies and percentages among AP users and non-users, and crude OR 
Ontario Switzerland 
AP usera AP non-userb AP usera AP non-userbDeterioration of 
behaviour Freq % Freq %
Crude OR














































































a: baseline samples were residents receiving antipsychotics and displaying the behaviour of interest at T1 (in brackets) 
b: baseline samples were residents not receiving antipsychotics and displaying the behaviour of interest at T1 (in brackets) 
6.3.3. Multivariate Analyses 
Only models where antipsychotic use was a significant predictor are presented here. Other models can 
be found in Appendix H. 
Cessation and improvement of wandering behaviour in Switzerland
In the Swiss sample, antipsychotic users were less likely to stop and reduce the display of wandering 
behaviour compared to non-users (tables 16 and 17). The same characteristics predicted the cessation 
and the reduction of wandering: residents with greater cognitive impairment were less likely to stop or 
improve wandering behaviour, while residents with greater ADL impairment were more likely to stop 
or improve wandering behaviour.  
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Table 16. Results of logistic regression analysis for predicting the cessation of wandering 
behaviour in Switzerland 
Variables Parameter 
estimate (SE) 
p-value Adjusted OR (95% CI) 
Intercept 0.81 (0.92)   
Antipsychotic use -0.67 (0.39) 0.0854 0.51 (0.24-1.10) 
ADL impairment (severe vs mild) 1.51 (0.57) 0.0087 4.50 (1.46-13.87) 
Cognitive impairment (severe vs mild) -2.28 (0.96) 0.0176 0.10 (0.02-0.67) 
Model fit: LR χ2=22, df=5, p=0.0006    C statistic: 0.71    Hosmer-Lemeshow: p=0.99 
 
Table 17. Results of logistic regression analysis for predicting the improvement of wandering 
behaviour in Switzerland 
Variables Parameter estimate (SE) p-value Adjusted OR (95% CI) 
Intercept 1.16 (0.62)   
Antipsychotic use -0.66 (0.36) 0.0641 0.52 (0.26-1.04) 
ADL impairment (severe vs mild) 1.49 (0.59) 0.0109 4.45 (1.41-14.04) 
Cognitive impairment (continuous) -0.5 (0.15)  0.0012 0.61 (0.45-0.82) 
Model fit: LR χ2=21, df=4, p=0.0003    C statistic: 0.70    Hosmer-Lemeshow: p=0.78 
 
Cessation and improvement of physically abusive behaviour in Ontario
In Ontario, antipsychotic use was inversely associated with the cessation and reduction of physically 
abusive behaviour: users were less likely to stop and reduce the display of physical abuse compared to 
non-users (tables 18 and 19). Residents displaying socially inappropriate and verbally abusive 
behaviour were also less likely to stop and improve physically abusive, while residents in pain were 
more likely to stop and improve compared to residents not in pain. 
Table 18. Results of logistic regression analysis for predicting the cessation of physically abusive 
behaviour in Ontario 
Variables Parameter estimate (SE) p-value Adjusted OR (95% CI) 
Intercept -1.26 (0.29)   
Antipsychotic use -0.76 (0.36) 0.0337 0.47 (0.23-0.94) 
Soc. inappropriate behaviour -0.77 (0.34) 0.0241 0.31 (0.13-0.77) 
Pain 
- Mild vs none 










Model fit: LR χ2=24, df=4, p<.0001    C statistic: 0.70    Hosmer-Lemeshow: p=0.24 
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Table 19. Results of logistic regression analysis for predicting the improvement of physically 
abusive behaviour in Ontario 
Variables Parameter estimate (SE) p-value Adjusted OR (95% CI) 
Intercept -0.87 (0.29)   
Antipsychotic use -0.68 (0.31) 0.0255 0.50 (0.28-0.92) 
Verbally abusive behaviour -0.61 (0.31) 0.0521 0.54 (0.29-1.01) 
Half bed rail 0.85 (0.34) 0.0125 2.34 (1.12-4.56) 
Pain 
- Mild vs none 










Model fit: LR χ2=33, df=5, p<.0001    C statistic: 0.72    Hosmer-Lemeshow: p=0.97 
 
Initiation and improvement of socially inappropriate behaviour in Switzerland
In the Swiss sample, antipsychotic use predicted the initiation of socially inappropriate behaviour, along 
with wandering, being verbally abusive, and being cognitively impaired (table 20). 
Table 20. Results of logistic regression analysis for predicting the initiation of socially 
inappropriate behaviour in Switzerland 
Variables Parameter estimate (SE) p-value Adjusted OR (95% CI) 
Intercept -4.15 (0.40)   
Antipsychotic use 0.73 (0.31) 0.0189 2.07 (1.13-3.82) 
Wandering 0.85 (0.36) 0.0172 2.35 (1.16-4.73) 
Verbally abusive 0.90 (0.36) 0.0038 2.46 (1.34-4.54) 
Cognitive impairment 







Model fit: LR χ2=38, df=5, p<.0001    C statistic: 0.75    Hosmer-Lemeshow: p=0.55 
In the Swiss sample, antipsychotic use was also inversely associated with the improvement of socially 
inappropriate behaviour (table 21). Not being physically impaired and insomnia were other predictors.  
Table 21. Results of logistic regression analysis for predicting the improvement of socially 
inappropriate behaviour in Switzerland 
Variables Parameter estimate (SE) p-value Adjusted OR (95% CI) 
Intercept -0.35 (0.36)   
Antipsychotic use -0.86 (0.39) 0.0253 0.42 (0.20-0.90) 
Insomnia 0.90 (0.47) 0.0541 2.46 (0.98-6.17) 
ADL impairment 
- moderate vs mild 
 





Model fit: LR χ2=17, df=4, p=0.0023    C statistic: 0.69    Hosmer-Lemeshow: p=0.81 
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Deterioration and cessation of aggressive behaviour in Ontario
In Ontario, antipsychotic use was negatively associated with the cessation of aggressive behaviour in 
logistic regression analyses: users were less likely to stop displaying aggressive behaviour than non-
users (table 22). Residents with depressive symptoms, longer length of stay, and who have chairs 
preventing raising were less likely to stop, while female residents and residents suffering from pain and 
dementia were more likely to stop displaying aggressive behaviour.  
Table 22. Results of logistic regression analysis for predicting the cessation of aggressive 
behaviour in Ontario 
Variables Parameter Estimate (SE) p-value Adjusted OR (95% CI) 
Intercept -1.14 (0.46)   
Antipsychotic use -0.85 (0.36) 0.0193 0.43 (0.21-0.87) 
Female 0.92 (0.35) 0.0089 2.50 (1.26-4.98) 
LOS 
- 1-3 yrs vs <1 yr 
- 3-5 yrs vs <1 yr 













Dementia 0.76 (0.28) 0.0075 0.47 (0.27-0.82) 
Depressive symptoms 
- moderate vs none 










Chair -0.61 (0.34) 0.0684 0.54 (0.28-1.05) 
Pain 
- moderate vs none 










Model fit: LR χ2=56, df=11, p<.0001    C statistic: 0.76    Hosmer-Lemeshow: p=0.35 
In Ontario, antipsychotic use predicted the deterioration of aggressive behaviour in logistic regression 
analyses (table 23), along with having sleep problems, being cognitively impaired, receiving anxiolytics 
and being trunk restrained. Residents receiving antidepressants were less likely to deteriorate. 
Table 23. Results of logistic regression analysis for predicting the deterioration of aggressive 
behaviour in Ontario  
Variables Parameter estimate (SE) p-value Adjusted OR (95% CI) 
Intercept -1.76 (0.28)   
Antipsychotic use 0.32 (0.19) 0.0832 1.38 (0.96-1.99) 
Insomnia 0.42 (0.22) 0.0560 1.52 (0.99-2.33) 
CPS impairment 







Antianxiety 0.37 (0.21) 0.0793 1.45 (0.96-2.18) 
Antidepressant -0.53 (0.21) 0.0131 0.59 (0.39-0.89) 
Trunk restraint 0.61 (0.37) 0.0973 1.84 (0.89-3.80) 




This study examined residents’ characteristics in general, prevalence rates and determinants of 
antipsychotic administration, and behavioural outcomes associated with their use in nursing home 
residents from two different countries, using common measures allowing international comparisons and 
benchmarking. As few studies previously compared resident characteristics in Switzerland and Canada, 
results from this international comparison of care settings are discussed first. Secondly, patterns of 
antipsychotic administration are discussed and compared between the two countries. Thirdly, the results 
from the investigation of predictors of antipsychotic administration are discussed separately in the two 
countries. Fourthly, results from the investigation of behavioural outcomes associated with the 
administration of antipsychotics in actual practice are discussed. Finally, limitations of this study are 
presented, followed by suggestions for future research and implications for practice and policy. 
7.1. Comparison of Resident Characteristics  
This study is one of the first to compare nursing homes residents in Ontario and in a German-speaking 
canton in Switzerland. Results of this international comparison revealed many differences in resident 
characteristics. Although these differences may be due to coding practices, it likely reflects differences 
in the types of residents admitted in nursing homes, as the MDS has demonstrated good reliability in 
international comparisons (Sgadari et al., 1997). 
The resident profile was clearly less severe in the Swiss sample than in Ontario, as indicated by 
the significantly lower proportion of residents with multiple diagnoses, psychiatric diagnoses, dementia 
and severe impairment in cognition and functioning, and confirmed by the lower case-mix index for 
Swiss residents compared to Ontario residents. This lighter care resident profile in Swiss nursing homes 
has previously been reported (Gobert & D’horre, 2005) and could be the result of admission policies. 
Indeed, nursing homes in Switzerland may function as a residential facility for some residents seeking 
social support rather than medical care per se (Ribbe et al., 1997). Access to nursing homes is more 
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strongly regulated in Ontario, leading to the admission of heavier-care residents. Also, the availability 
of beds for Swiss elderly patients in geriatric wards of general hospitals and in psychiatric hospitals 
may explain the less complex medical conditions of residents in nursing homes.  
The difference in the proportion of patients with dementia was salient: over half of the residents 
in Ontario were diagnosed with dementia compared to a fifth of the residents in the Swiss sample. Rates 
of dementia in different countries have previously been found to vary substantially.  For example, rates 
ranged from 19% in Sweden to 65% in Finland (PricewaterhouseCoopers LLP, 2001). Reasons for such 
discrepancies may be related to admission practices, treatment approach, or may be due to under-
diagnosis. Indeed, when examining the rate of dementia per year of assessment, it appeared that 35% of 
the residents assessed in 2002 had a diagnosis of dementia, compared to 20% or less of residents 
assessed between 1999 and 2001. This finding suggests that dementia was under-diagnosed in the 
sample before 2002. The rate of dementia was also examined at admission and at follow-up for 
residents admitted between 2000 and 2002: the rate of dementia decreased at follow-up, denoting that 
residents diagnosed with dementia at admission were reassessed as not having dementia six months 
later. This finding was very surprising and no clear explanation was found, warranting further 
investigation. Alternatively, cognitive impairment can be measured with the CPS in the MDS. Based on 
this scale, 32% of the Swiss residents were severely cognitively impaired. Thus, the CPS appeared to be 
a more reliable item to measure cognitive impairment in the Swiss-MDS than diagnosis of dementia.  
Swiss residents also suffered less from behaviour disturbances than Ontario residents, as 
illustrated by the much lower prevalence of physically abusive, socially inappropriate, resisting care and 
aggressive behaviour in general. One explanation for this great difference in the rate of behaviour 
disturbances may reside in the degree of tolerance for behavioural symptoms by the medical staff. 
Medical training and culture can greatly influence how nurses react towards residents who act out, how 
they consider what constitutes socially inappropriate and resisting care behaviours. Another explanation 
may be that the manifestation of aggressive behaviour is influenced by cultural factors (Fuh et al., 
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2002). Thus, the lower prevalence in Switzerland may indicate that residents truly display less 
behavioural symptoms or that staff are more tolerant towards behavioural symptoms. One may also 
argue that this lower prevalence of behavioural symptoms is due to the effective use of antipsychotics in 
agitated residents, suppressing their agitated symptoms. However, results from the study do not support 
this hypothesis, as antipsychotic use was preventative of behavioural cessation and improvement. 
Another pronounced difference was the higher proportion of male residents in the Swiss sample 
compared to Ontario. However, the proportion of males in nursing homes from other cantons in 
Switzerland (Lucas et al., 2004; Gobert & D’horre, 2005) was similar to Ontario. This difference likely 
reflects intrinsic characteristics of the Swiss sample and is not representative of residents in general.  
7.2. Patterns of Antipsychotic Use 
Antipsychotics were administered to 25% of the residents in the Ontario sample in 2001. This estimate 
was similar to the estimate reported by Bronskill and colleagues (2004) for the same period. In 
comparison to prevalence rates in nursing homes from other countries, the rate was higher than in the 
US, where antipsychotics are strongly regulated, and similar to other countries without regulations such 
as Iceland, Italy and the UK (Liperoti et al., 2003; Hughes et al., 2000; Oborne et al, 2002).  
The aggregated rate of antipsychotic use between 1999 and 2002 was 29% in the Swiss sample. 
This rate is lower than other estimates reported in French-speaking cantons in Switzerland (Lucas et al., 
2004; Gobert & D’horre, 2005). This difference may be due to the profile of the nursing homes 
included in the sample. For instance, in Lucas and colleagues’ study (2004), the sample included 
nursing homes specialized in psychiatric conditions, admitting more psychiatric cases for whom 
antipsychotics are likely prescribed, hence inflating the rate of antipsychotic administration.  
In comparison to Ontario, antipsychotic administration was surprisingly more common in 
Switzerland. Given the lower prevalence of psychiatric diagnoses and behaviour disturbances in the 
Swiss sample, one might have predicted a lower rate in the Swiss sample. This higher rate in the Swiss 
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sample could be due to a different classification system for medications and availability of medications. 
This could be the case for a medication called Distraneurin® which is coded as an antipsychotic in the 
Swiss MDS and is not available in Ontario. However, physicians from three of the nursing homes in 
Switzerland reported that this medication was only rarely administered (Dr. R. Gilgen, personal 
communication, March 17, 2006), reducing this potential bias. On the other hand, the lower prevalence 
of antipsychotic use in Ontario was mitigated by the more widespread use of chair restraints compared 
to Switzerland, possibly indicating the use of physical restraint instead of chemical restraint for some 
residents with behaviour disturbances. Previous studies have already raised concerns about the overuse 
of restraints in Canada compared to other countries (e.g. Jensdottir et al., 2003; Teare, Hirdes, Ziraldo, 
Proctor & Nenadovic, 2000). 
When adjusting for nursing home case-mix profile, rates of antipsychotic prescription among 
high- and low-risk residents were higher than in the US, suggesting antipsychotic misuse in both 
settings. The risk-adjusted rates were also higher in Switzerland than in Ontario. In particular, the high 
rate of antipsychotic use among low risk residents – residents with potentially inappropriate conditions - 
in the Swiss sample (25%) raises serious concerns about the appropriateness of their administration in 
nursing homes in Switzerland. Indeed, among residents receiving antipsychotics, 60% did not have a 
diagnosis of schizophrenia and did not display psychotic symptoms or agitated behaviours associated 
with cognitive impairment. In comparison, the rate among low-risk residents was 14% in Ontario, and 
34% of users had potentially inappropriate conditions. These results suggest that antipsychotics may be 
prescribed for convenience purposes rather than for treatment of targeted conditions or symptoms. 
A possible reason for the difference in rates of inappropriate use may reside in the type of 
physicians prescribing medications to residents, as suggested by a previous study in Ontario (Dhalla et 
al., 2002). In this study, inappropriate prescribing in general after nursing home admission was 
predicted by physicians’ characteristics, such as having more than one prescriber, a non-specialist 
physician and having a physician older than 50. This may also hold true in Switzerland and could be a 
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factor explaining the rate differences. Finally, the potentially inappropriate use found in Switzerland 
contradicts the results from Gobert and D’horre (2005), who considered antipsychotic administration to 
be appropriate in Switzerland, based on dosage and average practice. Thus, this study illustrates the 
importance of considering resident’s medical and clinical characteristics in addition to dosage and 
average practice to assess appropriateness. 
With regards to change in antipsychotic administration, most residents in the two countries 
remained free of antipsychotics or on antipsychotics at both baseline and follow-up. However, change 
did occur for a substantial number of residents, suggesting that residents do not remain on 
antipsychotics indefinitely. However, firm conclusions on whether guidelines for discontinuation of 
treatment were followed can not be made, as recommendations vary according to the targeted 
symptoms. Upon comparison of results in the two countries, the incidence and cessation rates were 
higher in Switzerland than in Ontario. The longer follow-up period in Switzerland likely allowed for the 
inclusion of more cases of initiation and discontinuation of treatment. This preliminary finding suggests 
that the rate of discontinuation/initiation increases with the length of follow-up. To determine whether 
this trend is linear requires longer follow-up periods.  
Results from the cross-sectional time pattern of antipsychotic administration in Swiss nursing 
homes showed an important increase in the overall rate over time (from 23% in 1997 to 41% in 2004), 
as well as an increase in the rates at admission. Unfortunately, such data were unavailable in the Ontario 
dataset. Results from the time series of antipsychotic utilization among all community-dwelling 
individuals residing Ontario over 65 years old, from 1993 to 2002 (Rapoport et al., 2005) indicated an 
increasing trend as well. The authors also noted that atypical antipsychotics, while not available in 
1993, accounted for 82% of the prescriptions by 2002. The increase in the administration of 
antipsychotics appears to be a global phenomenon both in Switzerland and Canada, likely due to the 
introduction of atypical agents. Thus, strategies to reduce antipsychotic administration are needed, 
targeting physicians and geriatricians both in nursing homes and in private practices in both countries. 
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Finally, results from the comparison of antipsychotic use at admission and at reassessment in 
Switzerland warrant discussion. First, the rate of antipsychotic use at admission for residents with 
longer stays was higher than the rate at admission for residents who were discharged within 5 months. 
This finding may be explained by the fact that residents with extended lengths of stay likely have more 
serious conditions which warrant the administration of antipsychotics. It would be also interesting to 
compare rates among residents admitted from the community with those admitted from hospitals. As 
this subject was not the primary focus of this study, future research should investigate the differences in 
characteristics between short and long stay residents, and antipsychotic users and non-users at 
admission, to better understand these findings. Second, the rate at reassessment was higher than at 
admission for most years, suggesting that nursing homes were responsible for a large number of 
antipsychotic prescriptions. The rate at reassessment in 2003 and 2004 was of special concern: almost 
half the residents who were admitted 5 months prior to assessment were receiving antipsychotics.  
7.3. Determinants of Antipsychotic Use 
This study identified a range of characteristics concurrently associated with antipsychotic use in 
multivariate analyses in both samples (16 and 10 variables in the Ontario and Swiss samples 
respectively). Psychiatric conditions, health conditions (cognitive and physical impairment), 
behavioural symptoms, demographic characteristics, and interventions predicted the administration of 
antipsychotics. Most determinants differed between the two countries, suggesting different practice 
patterns when antipsychotics were not administered for schizophrenia and bipolar disorders.  
The psychiatric diagnoses of schizophrenia and bipolar disorder were the strongest determinants 
in both settings. This finding was not surprising, as these psychiatric conditions are the principal target 
of antipsychotic treatment. Upon closer examination, 21% of antipsychotic users were diagnosed with 
schizophrenia or bipolar disease in Ontario, whereas only 9% of users in the Swiss sample. This finding 
suggests that these psychiatric conditions determine administration of antipsychotics for only a minority 
of residents, especially in Switzerland. While antipsychotic use was associated with psychotic 
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symptoms such as delusions and hallucinations in bivariate analyses in both samples, only the presence 
of delusions emerged as a determinant in multivariate analyses in the Swiss sample. The lack of 
association in Ontario suggests that antipsychotic administration was not primarily determined by the 
presence of psychotic features. However, it may also be possible that psychotic symptoms were present 
in users but not recorded in the MDS, leading to the absence of association.  
In Ontario, residents with major symptoms of depression were more likely to receive 
antipsychotics than those without such symptoms. However, having a diagnosis of depression was not 
associated with AP use. This finding implies that antipsychotics were not prescribed to treat diagnosed 
depression per se. Yet, half of antipsychotic users displayed depressive symptoms, suggesting that 
antipsychotics may cause or worsen depressive symptoms in cognitively impaired residents. Future 
research is needed to investigate this association in more depth. 
 Residents diagnosed with an anxiety disorder were also more likely to receive antipsychotics in 
Ontario. This finding suggests that antipsychotics were inappropriately prescribed to treat anxiety 
disorders in Ontario, as antipsychotics are not indicated to treat anxiety disorders (Alexopoulos et al., 
2004). Receiving anxiolytics or hypnotics was also associated with receiving antipsychotics, suggesting 
that anxiolytics/hypnotics were administered concomitantly with antipsychotics, possibly for their 
sedative effect as a treatment for agitated behaviours associated with dementia, as recommended by 
experts (Alexopoulos et al., 2004). Contrasting previous findings, antidepressant use was not longer 
associated with antipsychotics in multivariate analyses (e.g. Lindesay et al., 2003). As antipsychotics 
combined with antidepressant is a first line treatment for depression with psychotic symptoms 
(Alexoploulos et al., 2004), this finding suggests that antipsychotics were not predominantly prescribed 
for such indication in either country. 
The finding that cognitive impaired residents and residents diagnosed with dementia were more 
likely to be administered antipsychotics in both samples is consistent with previous studies (e.g. Voyer 
et al., 2005; Draper et al., 2001). Indeed, as cognitive impairment increased, so did the likelihood of 
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receiving antipsychotics.  There also seems to be a ceiling effect, as very severely impaired residents 
were less likely to receive antipsychotics than severely and moderately impaired residents. This 
association is likely due to the presence of agitation in cognitively impaired individuals with dementia 
(Cohen-Mansfield, Marx & Rosenthal, 1990), leading to antipsychotic administration. Although 
cognitive impairment likely precedes antipsychotic use, we can not exclude the possibility that 
antipsychotic use triggered or exacerbated cognitive loss, as suggested by McShane et al (1997).  
Consistent with previous studies (e.g. Voyer et al., 2005; Sorensen et al., 2001), sleep 
disturbances were associated with antipsychotic administration in the Swiss sample. Antipsychotics 
may be administered for their sedative effect to treat insomnia, as almost a quarter of users had sleep 
problems in Switzerland. However, according to guidelines, antipsychotics are not appropriate to treat 
insomnia, for which hypnotics or antidepressants are recommended (Alexopoulos et al., 2004). Though 
it can not be excluded that sleep problems were caused by antipsychotic intake, this finding suggests 
that antipsychotics are inappropriately prescribed to treat insomnia in Swiss residents.  
In the Ontario sample, displaying physically abusive and socially inappropriate behaviours 
emerged as significant determinants, while verbal abuse and resisting care were no longer associated 
with antipsychotic use. This finding suggests that the bivariate association between antipsychotics and 
verbal abuse and resisting care was probably confounded by physically abusive behaviour. Indeed, 
verbally abusive and resisting care behaviours were present in 70% and 90% of physically abusive 
residents respectively. Thus, these results suggest that physically abusive and socially inappropriate 
behaviour were the symptoms that triggered antipsychotic treatment in Ontario. On the contrary, 
behavioural symptoms no longer determined antipsychotic use in multivariate analyses in Switzerland. 
This finding is rather surprising, suggesting that antipsychotics were not primarily administered to 
control behavioural problems in Switzerland. In addition, wandering residents in the Ontario sample 
were more likely to receive antipsychotics, even when adjusting for the presence of dementia and 
cognitive impairment. The relationship may indicate that antipsychotics were prescribed to control 
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wandering behaviour (though they are not recommended to treat wandering) or that wandering is a side 
effect of antipsychotic use. The longitudinal results favoured this second interpretation, as users were 
more likely to start wandering and less likely to stop wandering compared to non-users. 
Nearly half of antipsychotic users were restless in both samples, but restlessness was associated 
with antipsychotic use in multivariate analysis in Switzerland only. Consistent with previous studies 
(e.g. Nygaard et al., 1994), the association with restlessness may indicate that antipsychotics are given 
as treatment for this behavioural symptom associated with dementia, though not recommended for this 
kind of symptom. On the other hand, restless behaviour could also be due to antipsychotic side-effect.  
Consistent with previous studies (e.g. Ruths et al., 2001; Lindesay, Matthews and Jagger, 2003), 
gender was no longer associated with antipsychotic use in multivariate analyses. As suggested, the 
relationship between gender and antipsychotic was confounded by age. The overuse by men in bivariate 
analyses was likely due to their younger age, which was independently associated with the likelihood of 
receiving antipsychotics in Ontario. Indeed, the odds of residents under 65 to receive antipsychotics 
were twice the odds of residents older than 85, consistent with previous findings (e.g. Voyer et al., 
2005). This association may be explained by the fact that antipsychotics are more likely given to 
individuals in better health (i.e. younger residents) because of their side-effect profile. 
In Ontario, being in a dementia care unit increased the likelihood of receiving antipsychotics. 
Almost half of the residents in these units received antipsychotics in Ontario, and over half of the 
residents in Swiss dementia units were receiving them. Although these units are usually designed to 
provide comprehensive care to patients with behavioural and cognitive problems, possibly favouring 
alternatives to pharmacological treatments, our finding suggests that antipsychotic administration 
remains the dominant approach to manage behaviours in these units. As previously reported (Sloane et 
al, 1991; Phillips, Spry, Sloane & Hawes, 2000), these specialized units are not successful in reducing 
pharmacological treatment of behaviour disturbances. The number of residents with cognitive and 
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behavioural problems may drive staff to administer antipsychotics in fear of an overwhelming workload 
alternative strategies would involve.  
In the Swiss sample, the prevalence of antipsychotics by facility ranged from 23% to 34% and 
the facility emerged as an independent determinant: being in the nursing home with the highest rate of 
AP use increased residents’ likelihood of receiving antipsychotics, regardless of clinical or behavioural 
characteristics. This finding is consistent with Lucas and colleagues’ results (2004), where the nursing 
home variable explained 20% of the variance in antipsychotic prescribing in Switzerland. These 
findings raise concerns about the possible non-rational administration of antipsychotics, such as 
physicians’ personal preferences or local habits. An explanation may also reside in number and type of 
physicians prescribing medications to residents. In two of the four nursing homes in Switzerland, 
residents were followed by their treating physician prior to entry, resulting in prescriptions originating 
from about 30 physicians, while a unique physician from a nearby hospital prescribed medications in 
another of the nursing homes (Dr. R. Gilgen, personal communication, March 17, 2006). Though it 
could not be determined whether the nursing home with the lowest rate was the one with a single 
physician, this hypothesis should be tested in future research. 
Antipsychotic administration was also associated with an evaluation by a mental health specialist 
within the last 3 months in Ontario. This finding suggests that specialists were consulted when 
prescribing antipsychotic treatment. However, mental health specialists were only consulted for 9% of 
antipsychotic users in Ontario. In contrast, mental health specialists were very rarely consulted in 
Switzerland, suggesting that such service was not available for residents. Residents confined to a chair 
to prevent them from rising were more likely to be receiving antipsychotics in Ontario, suggesting that 
chair restraints were used conjointly with antipsychotic treatment in Ontario nursing homes to manage 
behaviour disturbances. 
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7.4. Behavioural Change in Residents 
Before examining behavioural change associated with antipsychotics, a general overview of 
behavioural change in residents in both countries is presented. 
The display of behavioural symptoms remained stable for most residents, whether or not they 
displayed behavioural symptoms at baseline. Nevertheless, more residents started displaying agitated 
behaviour over time than stopped displaying it in both countries, as the overall prevalence rate of all 
types of behavioural symptoms increased over time. This suggests that residents’ behaviours deteriorate 
with time. This trend is likely caused by the deterioration of cognitive impairment over time, as 
previous studies have shown that the increase in cognitive impairment was associated with the 
worsening of agitated behaviours (e.g. Cohen-Mansfield, Marx & Rosenthal, 1990). The only exception 
was the lower rate of wandering behaviour at follow-up in the Swiss sample. One explanation may 
reside in the worsening of physical impairment over time, decreasing the ability of residents to wander. 
However, such trend in Ontario was not observed, suggesting a ceiling effect of the impact of physical 
impairment on wandering behaviour.  
Results also showed that less behavioural change occurred in Ontario residents than Swiss 
residents, as more residents resolved or improved their behavioural symptoms in the Swiss sample 
compared to the Ontario sample. These higher improvement rates did not appear to be due to the more 
widespread use of antipsychotics in Switzerland, as antipsychotics were not associated with behavioural 
improvement. This difference may be explained by the level of behaviour symptoms expressed in 
residents. Residents in Ontario may display heavier forms of behaviour disturbance than in Switzerland, 
which may be more difficult to alleviate. This hypothesis can only be confirmed in future research if 
detailed information on behavioural symptoms is available.  
7.5. Behavioural Outcomes of Antipsychotic Use 
Most residents displayed behavioural symptoms at the same frequency at baseline and follow-up, 
whether they received antipsychotics or not. Nevertheless, bivariate results suggested that for residents 
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free of behavioural symptoms at baseline, those receiving antipsychotic drugs started displaying 
behavioural symptoms more often compared to residents who remained free of antipsychotics. As 
suggested by Kiely and colleagues (2000), behavioural symptoms may not be present at baseline in 
antipsychotic users because they were controlled for by the treatment, but developed later due to drug 
tolerance or their overall condition that triggered the administration of antipsychotics. 
For residents already displaying behavioural symptoms, use of antipsychotics appeared to hinder 
the improvement or cessation of most disruptive behaviours, as a higher proportion of non-users 
improved compared to users, in contrast to findings from Kiely and colleagues (2000). As well, 
although antipsychotics were not predictive of behavioural deterioration, a higher proportion of users 
compared to non-users deteriorated. These results suggest that antipsychotics were not effective in 
reducing behavioural symptoms. Although it can not be ruled out that behavioural deterioration was due 
to some unmeasured variable, such as overall severity of resident’s condition, antipsychotics may be 
responsible for this deterioration due to their associated side-effects resulting in the display of 
additional disturbing behaviours. For instance, the anti-cholinergic effects associated with 
antipsychotics were shown to cause confusion, delirium, visual hallucinations and irritability in users 
(Maixner, Mellow & Tandon, 1999; Neil, Curran & Wattis, 2003). As well, tardive dyskinesia can lead 
to anger, and acute extra-pyramidal symptoms and urinary retention may cause great discomfort in 
users, resulting in the display of disturbing behaviours (Maixner et al., 1999). Thus, based on the 
literature on antipsychotic side-effects, behavioural deterioration may be induced by side-effects of 
antipsychotics. 
Upon examination of the predictive power of antipsychotics on behavioural change while 
controlling for confounding factors, antipsychotic use predicted few behavioural changes, stressing the 
importance of considering confounding variables, such as cognitive impairment (strongest predictor of 
behavioural change). The significant behavioural outcomes also differed between the two countries, 
possibly due to the different prescription pattern.  
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In contrast to findings from Kiely and colleagues’ study (2000), the initiation of wandering 
behaviour in Ontario was no longer associated with antipsychotic use when confounding factors such as 
cognitive impairment and physical functioning were introduced into the model. However, results from 
the Swiss sample showed that among residents who wandered at baseline, those who were administered 
antipsychotics were less likely to reduce or completely stop wandering than non-users. Thus, receiving 
antipsychotics appeared to prevent residents from improving or resolving wandering behaviour. As 
suggested by Kiely and colleagues’ study (2000), one plausible explanation may be that wandering 
behaviour is provoked by akathisia, a well documented side-effect of antipsychotic medications, which 
can only be stopped or reduced with dose reduction or drug discontinuation. 
In Switzerland as well, antipsychotic users were more likely to start being socially inappropriate 
compared to non-users. In addition, antipsychotics prevented the reduction of socially inappropriate 
behaviour, as antipsychotic use was inversely associated with improving in this type of behaviour. 
These findings suggest that antipsychotics were not effective in reducing socially inappropriate 
behaviour. On the contrary, they appeared to trigger this kind of behaviour. Even though other agitated 
behaviours and cognitive impairment were controlled for, this association may be due to the overall 
condition of residents receiving antipsychotics that makes future disruptive behaviour more likely. 
Another interesting finding was that among residents displaying physically abusive behaviour, 
those who were not taking antipsychotics were more likely to stop or reduce physically abusive 
behaviour within the next months compared to users in the Ontario sample. This inverse relationship 
may indicate that antipsychotics were not effective in alleviating or reducing physically abusive 
behaviour. However, as the type of physical behaviour was unknown, this relationship may be 
explained by the fact that residents who were not being administered antipsychotics displayed milder 
forms of physical abuse which were more easily and rapidly handled than those displayed by 
antipsychotic users.  
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When considering the impact of antipsychotics on aggressive behaviour in general, it appeared 
that antipsychotics were inversely associated with the cessation of aggressive behaviour in Ontario. As 
explained above, this may be due to the severity of behaviours among residents who are receiving 
antipsychotics, hindering complete resolution of problems. However, antipsychotic use also predicted 
the deterioration of aggressiveness, suggesting that antipsychotics were not effective in controlling 
aggressive behaviour in general. 
In conclusion, these exploratory findings suggest that behavioural improvement was not due to 
antipsychotic use. On the contrary, antipsychotic use seemed to have prevented users from improving 
and resolving behavioural symptoms. Moreover, antipsychotics appeared to have triggered and 
exacerbated the display of some behavioural symptoms. These results raise questions about the use of 
antipsychotics as a long-term treatment for behaviour disturbances as evidence of behavioural reduction 
due to antipsychotic administration is lacking in actual practice.  
7.6. Limitations 
Despite the advantages of a large sample size and standardized assessment tool providing information 
on numerous demographic and clinical variables, limitations exist and warrant caution in the 
interpretation of the results and the generalization of findings.  
First, the use of secondary data has inherent constraints, such as the restricted use of variables 
present in the assessment tool. The MDS 2.0 does not provide information on the reasons associated 
with administering antipsychotics or the type, dose or number of antipsychotic drugs prescribed. Such 
information would have been useful for refining the appropriateness criteria. Further, facility-level 
variables, such as staffing level, medical approach, and prescribing practices, are not assessed in the 
MDS. Such information would have been useful to clarify the differences between the two countries. 
Indeed, facility factors may have contributed to the variation of antipsychotic administration between 
the two countries.  
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Second, the MDS assessment instrument may be completed differently in the two countries, 
although the MDS has demonstrated good inter-rater reliability in cross-national comparisons. Such 
differences may explain part of the variation in resident characteristics and behaviour patterns between 
the two samples. As stated, nursing staff in Switzerland may be more tolerant for some types of 
behaviours compared to staff from Ontario, leading to different criteria when completing the MDS. 
Third, the constraints of data protection in Switzerland limited the availability of residents’ date 
of birth. Information on age would have been useful for international comparison and as a variable for 
the analyses. It can be hypothesized that age is a predictor in Switzerland as well, and its inclusion in 
the model would likely increase the fit of the model without invalidating other predictors. 
Fourth, firm conclusions about the effect of antipsychotic use on behaviours in the longitudinal 
analyses were limited by the inability to control what happened between assessments. Indeed, whether 
the residents continuously took antipsychotics during the follow-up period was unknown. Non-users at 
T1 and T2 may have briefly used antipsychotics in between, or users may have stopped in between. 
However, antipsychotics are usually administered for at least 3 months before attempts of 
discontinuation, limiting the potential for this bias. Misclassification bias is more likely present for 
assessments of behavioural changes. For instance, if a resident wandered between T1 and T2 but not 
within the 7 days prior to assessment, they would be classified as non-wanderer at T2. These situations 
of misclassification may explain the small number of statistically significant relationships between 
antipsychotic use and behavioural change. The measurement of behavioural display at only two times 
was also a limitation, as behavioural change was found to vary considerably over time in cognitively 
impaired residents (van Reekum et al., 2002).  
Fifth, some of the longitudinal analyses in this research did not produce large enough sample size 
to reach significance. Thus, type II error may have occurred, where the relationship truly existed, but 
was too modest to be detected with the available sample size. Nevertheless, the results were included in 
this study for exploratory purposes.  
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Finally, the generalization of the results is limited by the fact that the samples in both countries 
were not representative of all nursing homes in the regions of interest, especially in Switzerland where 
the sample consisted of only 4 nursing homes. However, several findings in the Ontario sample, such as 
the rate of antipsychotic use, were consistent with previous studies in Ontario, suggesting that the 
Ontario sample may be somewhat representative of nursing homes in Ontario. In Switzerland, only 
results from studies in French-speaking cantons were available, which were somewhat different from 
this study. However, these differences are likely due to the distinctive long term care systems in French- 
and German- speaking cantons. 
7.7. Future research 
The results and limitations of this study revealed several areas that require further investigation. Indeed, 
the findings of potential inappropriate use of antipsychotics and the increasing trend over time 
demonstrated the need for ongoing assessment of antipsychotic prescribing in nursing homes. Such 
studies should also have access to the reason for prescribing antipsychotics to assess appropriateness in 
a more comprehensive fashion. Facility level characteristics should also be incorporated in future 
research on international comparisons of patterns of antipsychotic prescription. Such studies could 
examine the impact of staff training, physician characteristics, treatment and management approach.  
Future research should also investigate antipsychotic use from admission to discharge to examine 
the longitudinal pattern of administration on a wider time-frame. The longitudinal predictors of 
antipsychotic initiation and discontinuation should also be examined on large samples to clarify the 
directionality of the relationship between antipsychotics and several characteristics, including 
depressive symptoms, sleep disturbances, and cognitive impairment.  
In this study, antipsychotics were associated with a lower likelihood of behavioural improvement. 
However, more research is required to clarify why antipsychotics may prevent improvement. As such, 
future studies should have access to more details on behaviours and examine patterns of behavioural 
change at closer intervals and at more than two points in time to better understand the relationship 
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between antipsychotic use and behavioural changes. Indeed, previous studies have shown that 
behaviours change considerably over time in cognitively impaired residents, warranting a close 
monitoring to assess the impact of antipsychotics on behaviour.  
This study also uncovered differences between residents in Ontario and Switzerland that require 
further examination. First, the lower prevalence of behavioural symptoms in Switzerland would be an 
interesting focus area for qualitative research in order to understand the underlying causes of this 
difference and to determine whether it was due to a higher tolerance level for behaviour disturbances. 
This could be done through in-depth interviews with nursing home staff. Second, the low prevalence of 
dementia in Swiss residents and the fact that residents deemed to have dementia at admission were 
reassessed as not having dementia warrants further investigation.  
7.8. Implications for Practice and Policy 
Findings from this study question the extent and appropriateness of antipsychotic administration in 
nursing homes in Ontario and Switzerland, warranting changes in practice patterns and implementation 
of policies. Indeed, results from this study showed that antipsychotics were widely used in both 
countries. In addition, antipsychotic administration increased over time in the Swiss sample, reaching 
the prevalence rate of 43% in 2004. Furthermore, potentially inappropriate administration was 
substantial in both countries, especially in Switzerland where six out of ten users had inappropriate 
conditions. As well, some determinants of antipsychotic use that emerged from the analyses are not 
considered as appropriate indications. Thus, this section provides suggestions for reducing and 
improving antipsychotic administration in nursing homes, based on the findings and existing literature. 
Clear guidelines about the appropriate and inappropriate use of antipsychotics in the elderly 
should be widely disseminated among physicians to address potential inappropriate prescribing 
practices in these countries. Indeed, prescribing physicians may not always have up-to-date information 
on the use of antipsychotics and their effects in geriatric patients. This could be due to a lack of training 
in geriatric medicine, a lack of time to consult recent publications or the unavailability of clear 
78 
guidelines. Such information should emphasize on the definition of psychiatric conditions and 
symptoms responsive to antipsychotic treatment. For instance, as insomnia emerged as strong 
determinant in Switzerland, the inefficacy of antipsychotics to treat insomnia and the benefits of using 
hypnotics instead when appropriate should be stressed. In Ontario, the inappropriateness of 
antipsychotics for anxiety disorders should be emphasized. 
In Ontario, the fact that being in a dementia unit determined receiving antipsychotics implies that 
these units were not successful in reducing pharmacological treatment of behaviour disturbances. Thus, 
the design and utility of these units should be reassessed and enhanced to actually provide 
comprehensive care to patients with behavioural and cognitive problems favouring alternatives to 
pharmacological treatments.  
In Switzerland, antipsychotics appeared to be administered differently according to the facility, 
regardless of clinical characteristics. In response, educational programs targeted towards physicians and 
nurses could be implemented in nursing homes with high prevalence rates of antipsychotic use, 
informing staff about the appropriate and inappropriate use of antipsychotics and promoting alternative 
solutions to drug treatment. Staff education is an important step to reduce antipsychotic use, as one 
study pointed out the reluctance of nursing staff to discontinue drug treatment because they believed in 
the utility of antipsychotic drugs to control agitation.  Further, more than half the staff thought that drug 
withdrawal would result in worsening of behavioural problems (Cohen-Mansfield et al., 1999). Past 
educational interventions have successfully led to reductions in antipsychotic administration by 
improving selectivity and proposing alternatives to drug use (e.g. Avorn et al., 1992; Ray et al., 1993). 
In addition, reduction in drug administration did not result in more behaviour disturbance or greater 
physical functioning among residents or in increased levels of stress among staff. These findings are 
also supported by studies investigating the impact of antipsychotic withdrawal on residents’ behaviours 
(e.g. Cohen-Mansfield et al., 1999; van Reekum et al., 2002). Though most of these studies were based 
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on small sample sizes, the reproducibility of the findings suggests that the results are valid and 
generalizable to most nursing home residents.  
In addition, a consultant pharmacist could be appointed to nursing homes. The role of such 
pharmacist would be to review drug prescriptions to assess whether medications are appropriate to the 
resident’s condition and appropriate in terms of type and dosage, and whether drug interactions are 
minimized. Further, the determinants found in this study could be used to target residents for review. 
Such solutions have previously been implemented with success in Switzerland, where this strategy 
improved the adequacy and rationality of prescription, and decreased the overall drug costs (Rugli et al., 
2004). A consultant pharmacist was also appointed to nursing homes in the US as part of the OBRA 
regulations, with limited success due to physicians’ reticence to discontinue treatment when suggested 
(Stoudemire & Smith, 1996).  
Finally, policies restricting the use of antipsychotics for targeted symptoms and disorders in 
nursing home residents could be implemented in both countries. The experience of the implementation 
of the OBRA regulations in the US (presented in section 2.2.3) illustrates that regulations are effective 
in reducing the use of antipsychotic drugs as well as to use of physical restraints (Rovner et al., 1992; 
Shorr, Fought & Ray, 1994; Hughes et al., 2000). This legislation achieved this reduction by limiting 
the use of physical restraint and requiring documentation of the specific condition for which 
antipsychotic drug is prescribed, as well as requiring trials of dose reduction with the goal of 
discontinuing the drug unless clinically contraindicated.  
However, precaution should be taken that chemical restraints are not replaced with physical 
restraints, which are also associated with negative outcomes. Instead, emphasis should be placed upon 
other alternatives. As behavioural and psychosocial approaches require more staff time in general than 
pharmaceutical or restraining approaches, funding from public sources ought to be increased to enable 
nursing homes to initiate changes. Such funding could be used for training existing staff and hiring 
additional staff to deal with psychotic and agitated residents and alleviate work load, for training 
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physicians caring for elderly individuals, and for implementing educational programs and appointing 
consultant pharmacists. 
7.8.1. Implications for the MDS Quality Indicator for Antipsychotic Use 
Based on the findings of this study, it is  recommended that the QI for antipsychotic use be retained in 
Ontario and Switzerland, unlike in the US where this QI is no longer recommended for public reporting. 
Indeed, the situation of potentially inappropriate and excessive use in Ontario and Switzerland is quite 
dissimilar to the one in the US where the OBRA-87 regulations resulted in significant reduction of 
inappropriate and excessive antipsychotic administration to nursing homes residents (e.g. Liperoti et al., 
2003). For instance, the prevalence rate of antipsychotic use in US nursing homes (14%; Hughes et al., 
2000) was much lower than rates found in this study for Ontario and Switzerland. Since antipsychotic 
use remains problematic in nursing homes in Ontario and Switzerland, it is necessary to continue using 
this QI to detect inappropriate use; these reports could then inform strategies to reduce such use.  
As reviewed above, a number of strategies exist to reduce the administration of antipsychotics 
and enhance the appropriateness of prescribing practices. These strategies include: the implementation 
of regulations and policies restricting the prescription of antipsychotics to specific indications; the 
appointment of consultant pharmacist to nursing homes; the diffusion of comprehensive guidelines; the 
offering of educational programs aiming at physicians and nursing home staff; and the promotion of 
alternative strategies (e.g. environmental changes, behavioural or psychosocial programs). The 
reporting of the QI would also enable program-planners to target nursing homes with high rates of 
inappropriate use.  
7.8.2. Implications for the RAI-RAP for Psychotropic Drugs 
The care planning protocol for psychotropic drugs outlines that the need for the drug should be 
critically reassessed and that antipsychotic treatment should target specific behavioural symptoms or 
conditions and not be administered for convenience purposes. The RAP also encourages staff to clarify 
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the potential drug-related problems, such as mood and behavioural problems and describes when drug 
treatment should be discontinued. The RAP could further be improved in several points.  
Though the RAP concerns residents receiving any type of psychotropic, it is suggested that the 
first section describing the problem includes a paragraph on the specific concerns associated with 
antipsychotic drugs and on the extent of inappropriate use of antipsychotics in nursing homes. A link 
could also be added to the published guidelines on the appropriate and inappropriate indications for 
antipsychotic prescription in the elderly to help review the reason of administration and make a decision 
with regards to continuing the treatment.  
The presence of a diagnosis of depression as trigger item could be replaced with the presence of 
depressive symptoms as measured by the DRS to better capture the negative effects of antipsychotics 
on depression, as antipsychotics were associated with depressive symptoms rather than a diagnosis of 
depression. Further investigation on whether to include wandering as trigger item is recommended, 
because of its potential role as side-effect. The list of drugs should be regularly updated, as new 
antipsychotics were and will continue to be introduced.  
In step one of drug review, guidelines should include reviewing whether trials of dose reduction 
and discontinuation were attempted. As well, the reviewer should be encouraged to assess whether 
alternatives to pharmacological treatments were previously sought for residents with conditions that do 
not necessarily require antipsychotic treatment. The care planning protocol could also offer suggestions 
of alternative strategies to pharmacological treatments, as mentioned above. Finally, the guidelines 
should include a discussion on the detriments of replacing pharmacotherapy with physical restraint. 
8. CONCLUSION 
The care and management of behaviour disturbances and psychotic features in nursing homes residents 
is complex, especially in cognitively impaired residents. Thus, finding the best method to deal with 
these problems require much efforts. However, this should not hinder nursing home staff from finding 
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alternative strategies to antipsychotic treatment, as they are associated with many side-effects. Yet, 
findings from this study show that antipsychotics are excessively and inappropriately prescribed to a 
substantial amount of nursing home residents in both countries, but especially in Switzerland, as 
uncovered by international comparison with Ontario. In addition, the longitudinal results demonstrating 
a lack of association with behavioural improvement question their use as a long-term treatment for 
behaviour disturbances. Thus, changes in practice patterns and implementation of policies are warranted 
to improve prescribing practices and promote the quality of care provided to residents in nursing homes, 
as well as residents’ safety and well-being. 
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APPENDIX A: LITERATURE REVIEW OF THE EFFECTIVENESS OF ANTIPSYCHOTICS
1. Reviews and RCTs on effectiveness of neuroleptics (chronological order)





53 nursing home (NH)
residents
BPRS and SCAG as outcome measures Improvement for behavioural problems of anxiety,
excitement, emotional liability, uncooperativeness
Sunderland &
Silver, 1988
Qualitative review 20 double-blind and/or placebo-controlled
studies published between 1954 and 1986
60% of the studies demonstrated positive clinical results in
demented patient using neuroleptics. When used at low doses
for symptoms of dementia (agitation, hyperactivity,




Qualitative review 14 uncontrolled studies
15 double-blind controlled trials of
neuroleptics in dementia
Limited evidence to suggest that neuroleptics may be
effective in relatively low doses in some demented patients
with behavioural disturbance
Helms, 1985 Qualitative review 21 studies up until 1985 of antipsychotics in
the treatment of behavioural complications of
dementia
Only 3 studies met the quality criteria. Results were mixed
and antipsychotics showed moderate benefit in treating
certain symptoms associated with dementia.
Schneider et al,
1990
Quantitative meta-analysis Controlled trials comparing neuroleptics to
placebo published between 1962 and 1982
Neuroleptics were “significantly more effective than placebo
and had a small effect size”: 18% of patients with dementia
benefited from neuroleptic treatment.
McShane et al,
1997
2 year prospective study.
71 subjects with dementia
living at home
Cognitive function scores measured with the
MMSE, behaviour measured with PBE
22.5% on antipsychotics




Quantitative meta-analysis Randomized, controlled, double-blind trials
published between 1966 and 1995
The pooled mean percentage of patients who improved was
64% (54% to 72%). The therapeutic effect was 26%
(neuroleptic minus placebo). All neuroleptics had similarly
small but significant efficacy over placebo. Risk of side-
effects: 25%.
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2. Reviews and RCTs on effectiveness of atypical antipsychotics (chronological order)
Study Design / sample Outcome measure Results
Katz et al, 1999 double-blind, randomized,
placebo-controlled study
625 residents in NH and
chronic care hospital with
dementia
Efficacy and safety of risperidone in the
treatment of psychotic and behavioural
symptoms using the BEHAVE-AD scale as
main outcome measure.
Clinical improvement measured as the
percentage of patients with >50% reduction
on BEHAVE-AD total score
Risperidone users showed significantly greater reductions in
BEHAVE-AD total scores, and psychosis and aggressiveness
in subscales scores. Most common adverse events: EPS,
somnolence, peripheral oedema.
No significant change in cognition compared to placebo.




344 patients with dementia.
Comparison of risperidone with haloperidol
and placebo using the BEHAVE-AD and the
CMAI scores as outcome measures.
Clinical improvement measured as the
percentage of patients with >30% reduction
on BEHAVE-AD total score.
Risperidone was associated with greater reductions in the
severity and frequency of behavioural symptoms, particularly
aggression, in elderly patients with dementia, than placebo
and conventional. Their results did not show substantial
improvement in cognition.
Yoon et al, 2003 Prospective open-labelled
study in Korea
48 demented patients
Effect of risperidone on the BPSD using the
BPRS scale, on cognitive function using the
MMSE, and on ADL using the BADL scale
Risperidone was effective in significantly reducing the scores
on the BPSD (except anxiety subscale) without affecting
cognition and ADL (no significant change on scores)
Lee et al, 2004 Qualitative review 5 trials (Katz, DeDeyn, Brodaty, Street) on
the efficacy of atypical in the treatment of
behavioural and psychological symptoms of
dementia, and over conventional
antipsychotics
Treatment with atypical antipsychotics was superior to
placebo for improving BSPD and adverse events were
common (EPS, somnolence, abnormal gait).
Limited evidence supports the perception of improved
efficacy and adverse events compared to typical.
3. Clinical studies on effectiveness of antipsychotics (chronological order)
Study Design / sample Outcome measure Results
Burton et al,
1995
1 year longitudinal study.
201 residents in 8 skilled
NH in the US.
9 behaviours measured with PGDRS
collected with interviews, psychiatric
evaluations, and medical charts.
39.3% on neuroleptics within 1 year
A change in behaviour was more likely to occur in
neuroleptic users towards resolving or development of
disruptive behaviour
Kiely et al, 2000 Retrospective cohort study
8982 NH residents in 2 US
states
Incidence of wandering, measured with MDS Residents with short- and long-term memory problem,
pneumonia, asked repetitive questions, with dementia,
constipation, and used antipsychotic medications were at
increased risk for wandering.
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APPENDIX B: LITERATURE REVIEW OF STUDIES ON PREVALENCE AND CHARACTERISTICS ASSOCIATED
WITH ANTIPSYCHOTICS IN NURSING HOMES
(by chronological order)
Study Sample Design / Data collection method AP use (range) Associates
Ray et al, 1980 5,902 Medicaid patients
over 65 in 173 NH
(US)
Nursing home patient’s use of
neuroleptics, within 1 year of being
in a nursing home, using drug claims
43% Greater use among larger nursing home facilities
Lack of association with other facility factors (cost
per patient day, staff per bed)
Buck, 1988 All Medicaid recipients
in 1 state in the US (not
only elderly)
Retrospective exam of residents’
drug claims, within 1 year of being
in a nursing home
44% Prescriptions of neuroleptic were more influenced
by patient characteristics than institutional
variables. However, resident characteristics only
explained 10% of the variance in neuroleptic use.
Beers et al, 1988 850 residents in 12
intermediate care
facilities in the US
Use of a software program to capture
needed information, use within 1
month







residents in 112 NH in
the US
Data from the National Nursing
Home Study Pretest (which consisted





users: 6.7% had no mental disorders, 24% had an




1533 residents in 11
geriatric institutions in
Italy





301 residents in 11 NH
in Ireland
Drugs prescribed during 1-week
period
27% The rate of psychotropic drug prescribing was
inversely related to nursing home size.
Nygaard et al,
1990
1300 residents in 21
NH in Norway
1 week census data of resident
interviews by nurses
32.6 % No association with gender and age.
Restlessness and wandering, inability to perform





residents in 60 NH in 8
states (US)
Retrospective cohort study
(admission, 3 months later, at
discharge/end of study)
17%
(at each point of
time)
Neuroleptic use was associated in bivariate
analyses with younger age and physical restraint.
Spore et al, 1992 419 residents in 4 NH
in the US
Cross-sectional data using medical
records
23.2% Dementia, psychosis, frequency of agitation, level





in 5 NH in Norway
Prospective study
Information on variables by nurses
35% on admission
34% after 3 months
Dementia (OR=3.4), dependency (ADL) (OR=0.14
– 0.21), restlessness (OR=16.76) and problems in
short-term memory (6.13) were associated with
neuroleptic use in bivariate
Restlessness only (13.53) in multivariate
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dementia admitted to 1
NH in Holland between
Jan 1980 and dec 1989
Retrospective study of medical
records





909 residents in 28 NH
in the UK
Cross-sectional study of medical
files
24% Antipsychotics prescription was only appropriate
in 12% of users (using OBRA guidelines).
Wancata et al,
1997
262 residents in 10 NH
in Austria
Review of treatment sheets (data on









Sleeping patterns and psychiatric disorders were
significantly associated with psychotropic use in
general, but sociodemographic variables (gender,
age, marital status) and source of admission were
not associated
Suggest that a large percentage of psychotropic




298 residents in 7 NH
in the US between 1995
and 1996
Retrospective chart review 42% Not investigated.
Schmidt et al,
1998
1823 residents in 33
NH in Sweden
Cross-sectional review of patients’
medication list
34% (7 - 53) 29.2% of users had no psychotic diagnosis.
Conn et al, 1999 436 residents in 4 NH
in Ontario
Review of pharmacy files 29.8% Not investigated.
Castle, 1999 2088 residents in 268
NH in 10 states in the
US in 1993
Cross-sectional study using the MDS
for resident level variables and
OSCAR for facility level variables
16.9% Antipsychotic use associated with ADL, CPS, age,
gender, history of psychiatric problems, dementia,











Only impact of legislation was investigated.




647 residents in 11 NH
in Sydney
Review of nursing home charts and
interview with residents
21.3% Associated in bivariate analyses with delusions-,
hallucinations-, activity disturbance- and
aggressiveness-subscales of the BEHAVE-AD. In
multivariate with activity disturbance subscale,
dementia and psychosis.
Ruths et al, 2001 1552 residents in 23
NH in Norway
Information obtained from survey of
nurses and physicians
23% (0 - 61) Age and gender were associated with antipsychotic
use in bivariate analysis. Only age in logistic
regression. Facility variables (size, staff) not
significant.
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Study Sample Design / Data collection method AP use (range) Associates
Sorensen et al.,
2001
288 residents (65+) in
10 NH in Denmark
Cross-sectional analysis of
interviews and medical files
21% Associated with behavioural problems in bivariate
(resisting care, becoming easily upset, seeing/
hearing things not there, asking for attention,
pacing uncooperativeness). Associated in
multivariate with psychiatric morbidity (OR=8),
ADL impairment in transfer (OR 9.7) and in
mobility (OR=0.2), disturbing others during night




infirm residents in NH
in the UK
Cross-sectional study using
prescription sheets, and interviews
and MDS for clinical data
15.3% Antipsychotic use was associated in bivariate




934 NH residents in the
UK
Cross-sectional survey of medication
administration records







1 night census data using




Associated with younger age, type of home,
cognitive impairment, offensive behaviour, lower
ADL dependency, antidepressant use, urinary




1732 NH in the US
(1999-2000)
Cross-sectional study using the MDS 15% overall Among appropriate users: 68.3%
Among potentially appropriate users: 18.2%






between 1998 and 2000
in Ontario
Retrospective cohort study using
claims from the Ontario Drug
Benefit (ODB) program
17% within 100 days
of admission
24% within 1 year of
admission
New exposure to neuroleptics was less likely in




All 5884 NH residents
in the canton of Vaud
(Switzerland) in 1996
Cross-sectional analysis using an
administrative database (PLAISIR
system)
43% In multivariate linear regression, the number of
antipsychotics administered daily was negatively
associated with age, Parkinson’s disease, severe
orientation problems, drug-addiction and the size
of the nursing home. It was positively associated
with psychiatric morbidity, agitation, disturbing
others, impairment in daily decision making, and
persistent anxiety. Clinical variables explained








Retrospective analysis of MDS
assessments, medication
administration records, and Medicare
claims
27.6% (at least once
during study period)
With appropriate indication: 19.4%
No appropriate indication: 8.4%
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residents in Quebec and
7592 long-term care
residents in Switzerland






Common factors associated with antipsychotic use
in logistic regression were younger age, difficulties
in orientation, behavioural disorders, organic
psychotic state and other psychoses, and, for




2302 residents in 40
NH in Sydney in 2003
Cross-sectional study using clinical
files and medication cards recording
use of medication in the previous 4
weeks
25.1% 80% of nursing home residents who received
antipsychotics did not have a diagnosis of
schizophrenia. Most recipients had dementia or
cerebral disease.
Voyer et al, 2005 2332 residents in 28
NH in Quebec
Cross-sectional study using
interviews with nurses and review of
medical files
27.8% Factors associated with antipsychotic use in
logistic regression were younger age, few hours of
family visit, severe cognitive impairment,
insomnia, physical restraint, and disruptive
behaviour.
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APPENDIX D: RESIDENT ASSESSMENT PROTOCOL FOR PSYCHOTROPIC 





APPENDIX E: SELECTION OF THE ONTARIO AND SWISS SAMPLES 
 
1. ONTARIO SAMPLE December 1999 – February 2001 
 
2. SWISS SAMPLE August 1997 – October 2005 
 
19,276 (all assessments) from 4 nursing homes 
Discharged assessment deleted: 
15,837 assessments remaining
Admission assessments deleted: 
12,500 assessments remaining
Assessments between Jan 1999 and Dec 2002 only: 
6523 assessments remaining
1536 residents with one non-admission assessment 
between Jan 1999 and Dec 2002
1175 residents with reassessment ~156 days after non-
admission assessment 
Data transposed by resident and by date of assessment
Selection of first assessment to appear in dataset
4560 (all assessments) from 24 nursing homes 
1961 residents with one initial assessment 
1932 residents with valid entry for antipsychotic 
1540 residents with reassessment ~100 days after 
initial assessment 
Data transposed by resident and by date of assessment
Selection of first assessment to appear in dataset 
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APPENDIX F: TIME SERIES OF ANTIPSYCHOTIC USE IN SWITZERLAND 
 
Table 1. Prevalence of antipsychotic use for newly admitted residents by length of stay and by 
fiscal year in Switzerland 
 Antipsychotic use 
Newly admitted residents with short 
stay (not reassessed a)
Newly admitted residents with 
long stay (reassessed b)
All newly admitted 
residents 
Year Freq Percent Freq Percent Freq Percent 
1998 4/46 8.70 23/119 19.33 27/165 16.36 
1999 29/147 19.73 58/222 26.13 87/369 23.58 
2000 33/162 20.37 67/221 30.32 100/383 26.11 
2001 44/156 28.21 60/229 26.20 104/385 27.01 
2002 54/197 27.41 81/249 32.53 135/446 30.27 
2003 58/204 28.43 98/220 44.55 156/424 36.79 
2004 65/226 28.76 101/224 45.09 166/450 36.89 
2005 59/255 23.14 31/105 29.52 90/360 25.00 
Total 346/1393 24.87 519/1589 32.66 865/2982 29.01 
a: not reassessed because of discharge and/or because of pending reassessment for admission assessments in 2005 
b: reassessed at least once after admission 
Note: no admission assessments in 1997  
 
Table 2. Overall prevalence of antipsychotic use by fiscal year in Switzerland 
 Antipsychotic use 
Year N Freq Percent 
1997 111 24 22.62 
1998 1541 354 22.97 
1999 2185 613 28.05 
2000 1940 682 35.15 
2001 1998 707 35.39 
2002 2172 778 35.82 
2003 2114 799 37.80 
2004 2076 852 41.04 
2005 1696 632 37.36 
Total 15,837 5443 34.37 
Note: includes all assessments except discharge (more than 1 assessment per resident per year possible) 
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APPENDIX G: CHANGE IN BEHAVIOURS IN ONTARIO AND SWITZERLAND 
 






















Not wandering  
n = 1156




Not wandering  
n = 922
















Not verbal abuse  
n = 67




Not verbal abuse  
n = 991




Not verbal abuse  
n = 760
















Not physical abuse  
n = 28




Not physical abuse  
n = 1169
















































Not socially inap. 
n = 43




Not socially inap. 
n = 1018




Not socially inap. 
n = 926
















Not resisting care 
n = 46




Not resisting care 
n = 761




Not resisting care 
n = 882























































APPENDIX H: LONGITUDINAL MULTIVARIATE MODELS 
 
Table 1. Models of change in wandering behaviour: predictors in Ontario and Switzerland 
 Ontario Switzerland 
AP Other predictors AP Other predictors 
Initiation ns Positive: cognitive impairment, 
dementia, half-bed rails. 
Negative: pain and ADL impairment  
ni  
Cessation ni  negative Positive: ADL impairment 
Negative: cognitive impairment  
Improvement ni  negative Positive: ADL impairment 
Negative: cognitive impairment 
ns = not significant in multivariate model  
ni = not investigated in multivariate analyses because not significant in bivariate analyses 
 
Table 2. Models of change in verbally abusive behaviour: predictors in Ontario and Switzerland  
Ontario  Switzerland 
AP Other predictors AP Other predictors 
Initiation ns Positive: dementia, resisting care, being 
socially engaged, sleep disturbances, male 
Negative: full bed rails 
ns Positive: wandering, physically 
abusive behaviour, depressive 
symptoms 
Negative: ADL impairment 
Improvement ns Positive: shorter stay, pain 
Negative: inappropriate behaviour, ADL 
impairment 
ni  
ns = not significant in multivariate model 
ni = not investigated in multivariate analyses because not significant in bivariate analyses 
 
Table 3. Models of change in physically abusive behaviour: predictors in Ontario and Switzerland  
Ontario  Switzerland 
AP Other predictors AP Other predictors 
Initiation ni  ns Positive: male, verbally abusive, resisting care, 
cognitive impaired, depression 




Improvement negative Positive: pain, half bed rail 
Negative: verb. abusive 
behaviour 
ni  
ns = not significant in multivariate model 
ni = not investigated in multivariate analyses because not significant in bivariate analyses 
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Table 4. Models of change in socially inappropriate behaviour: predictors in Ontario and 
Switzerland  
Ontario  Switzerland 
AP Other predictors AP Other predictors 
Initiation ns Positive: male, dementia, resisting care, 
depressive symptoms, and Negative: 5+ 
diagnoses 
positive Positive: wandering,  
verbally abusive, cognitive 
impairment 
Cessation ni  ns Positive: male, verbally abusive, 
restless, having depressive 
symptoms 
Negative: 5+ diagnoses 
Improvement ni  negative Positive: insomnia 
Negative: ADL impairment 
ns = not significant in multivariate model 
ni = not investigated in multivariate analyses because not significant in bivariate analyses 
 
Table 5. Models of change in resisting behaviour: predictors in Ontario and Switzerland  
Ontario  Switzerland 
AP Other predictors AP Other predictors 
Improvement ns Positive: pain, shorter stay 
Negative: behaviour intervention, soc. inap. 
behaviour 
ni  
ns = not significant in multivariate model 
ni = not investigated in multivariate analyses because not significant in bivariate analyses 
 
Table 6. Models of change in aggressive behaviour: predictors in Ontario and Switzerland 
 Ontario  Switzerland 
AP Other predictors AP Other predictors 
Initiation ni  ns Positive: restless, cognitive 
impairment 
Negative: ADL impairment 
Cessation negative Positive: female, pain, dementia  
Negative: depressive symptoms, longer 
length of stay, chairs preventing raising  
ns Positive: pain 
Negative: restless, dementia 
Deterioration positive Positive: insomnia, cognitive 
impairment, antianxiety, trunk restraint 
Negative: antidepressant 
ni  
ns = not significant in multivariate model 
ni = not investigated in multivariate analyses because not significant in bivariate analyses 
 
